CN111684064A - 突变dna聚合酶 - Google Patents

突变dna聚合酶 Download PDF

Info

Publication number
CN111684064A
CN111684064A CN201980008824.4A CN201980008824A CN111684064A CN 111684064 A CN111684064 A CN 111684064A CN 201980008824 A CN201980008824 A CN 201980008824A CN 111684064 A CN111684064 A CN 111684064A
Authority
CN
China
Prior art keywords
leu
ala
glu
arg
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980008824.4A
Other languages
English (en)
Inventor
孟祥栋
郑旻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioradiation Laboratory Co ltd
Bio Rad Laboratories Inc
Original Assignee
Bioradiation Laboratory Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioradiation Laboratory Co ltd filed Critical Bioradiation Laboratory Co ltd
Publication of CN111684064A publication Critical patent/CN111684064A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/1252DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07007DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

提供了对一种或多种聚合活性抑制剂的抗性增加的突变A型DNA聚合酶。

Description

突变DNA聚合酶
相关申请的交叉引用
本申请要求于2018年1月19日提交的美国临时申请62/619,394的权益,该申请通过引用整体并入本文。
关于以文本文件形式提交的序列表
将12.12.18于机器型号IBM-PC,MS-Windows操作***创建的82,590字节的文件094260-1116788_115810PC_SL.txt中所记载的序列表全文纳入本文用于所有目的。
背景技术
核酸的检测,分析,转录和扩增是现代分子生物学中经常使用的程序。聚合酶链反应(PCR)是这种常用方法的一个示例。PCR用于研究基因表达以及在传染病或遗传病的诊断中,仅举几个例子。
PCR的一个组分是DNA聚合酶,其合成与DNA区段互补的新DNA。已经发现了多种热稳定的聚合酶。已知至少5个DNA-依赖性DNA聚合酶家族,虽然大多数落入A、B和C家族。各家族之间几乎没有或没有结构或序列相似性。大多数A家族聚合酶是可含有多重酶促功能(包括聚合酶、3′到5′核酸外切酶活性和5′到3′核酸外切酶活性)的单链蛋白质。B家族聚合酶通常有具有聚合酶和3′到5′核酸外切酶活性的单个催化结构域,以及辅助因子。C家族聚合酶通常是具有聚合和3′到5′核酸外切酶活性的多亚基蛋白质。
在市场上可买到的许多不同聚合酶中,Taq DNA聚合酶(A型DNA聚合酶)是一种热门选择,因为它是热稳定,高效且易于生产的。然而,由于被测样品中存在的内源性聚合酶抑制剂或由于已经添加到样品中的抑制物质(例如,添加到血液样品中的抗凝剂),Taq DNA聚合酶的酶活性可能降低。
发明内容
本文提供了突变A型DNA聚合酶,其包含对应于野生型水生栖热菌(Taq)DNA聚合酶的一个或多个氨基酸残基551、788和798的突变。突变聚合酶比野生型DNA聚合酶对聚合活性抑制剂具有更高的抗性。在一些实施方式中,突变A型DNA聚合酶包含D551R,V788L和A798E处的突变。在一些实施方式中,突变A型DNA聚合酶在选自52、99、109、128、154、259、268和739的氨基酸残基处包含一个或多个其他突变。在某些实施方式中,突变A型DNA聚合酶包含L52A,I99M,A109E,K128I,H154A,A259R,R268G和S739R处的突变。在一些实施方式中,突变A型DNA聚合酶与选自SEQ ID NO:1、2、3、4、5、6和7的氨基酸序列具有至少85%的相同性(或至少90%,91%,92%,93%,94%,95%,96%,97%,98%,99%相同性)。在一些实施方式中,突变A型DNA聚合酶包含SEQ ID NO:1,SEQ ID NO:2,SEQ ID NO:3,SEQ ID NO:4,SEQ ID NO:5,SEQ ID NO:6或SEQ ID NO:7。在一些实施方式中,突变A型DNA聚合酶在98℃下热稳定持续至少15分钟。
在一些实施方式中,聚合活性抑制剂来自血液样品。在一些实施方式中,聚合活性抑制剂是抗凝剂。在某些实施方式中,聚合活性抑制剂是肝素。
还提供了一种组合物,其包含(i)如上所述或本文其他地方所述的突变A型DNA聚合酶,和(ii)选自水性缓冲剂,金属离子,核苷酸,引物,探针,去污剂,染料,检测剂和靶核酸的一种或多种试剂。
还提供了扩增靶核酸的方法。在一些实施方式中,该方法包括使疑似含有靶核酸的测试样品与上文或本文其他地方所述的突变聚合酶,特异性结合靶核酸的至少一种引物以及核苷酸接触以形成混合物;和
在允许由聚合酶使用靶核酸的序列作为掺入核苷酸的模板延伸至少一种引物的条件下,孵育混合物。在一些实施方式中,该方法是PCR。在一些实施方式中,该方法是qPCR,逆转录PCR(RT-PCR)或ddPCR。在某些实施方式中,所述条件包括以抑制野生型DNA聚合酶的浓度存在野生型DNA聚合酶的抑制剂。在一些实施方式中,测试样品是血液样品或血液组分。
还提供了一种核酸,其包含编码上文或本文其他地方所述的突变热稳定A型DNA聚合酶的核苷酸序列。还提供了包含上述或本文其他地方所述的核酸的载体。还提供了包含上述或本文其他地方所述的载体的宿主细胞。
还提供了产生多肽的方法。在一些实施方式中,所述方法包括在允许表达由所述核酸编码的多肽的条件下,在培养基中培养包含核酸的宿主细胞,所述核酸包含编码上文或本文其他地方所述的突变热稳定A型DNA聚合酶的核苷酸序列;和从培养的细胞或培养基中纯化多肽。
还提供了用于扩增靶核酸的试剂盒。在一些实施方式中,试剂盒包含(i)上文或本文其他地方所述的突变热稳定A型DNA聚合酶,和(ii)选自水性缓冲剂,金属离子,核苷酸,引物,探针,去污剂,检测剂,染料,抗凝剂和细胞裂解剂的一种或多种试剂。
附图说明
图1显示了示例性的A型DNA聚合酶(即Taq聚合酶,SEQ ID NO:8)和突变A型DNA聚合酶(SEQ ID NO:1-7)的比对。
具体实施方式
本文描述了对DNA聚合酶活性的抑制剂更具抗性的突变A型DNA聚合酶。遗传工程化或突变DNA聚合酶适用于核酸扩增方法,例如PCR,定量PCR(qPCR),逆转录PCR(RT-PCR)或数字液滴PCR(ddPCR)。
I.定义
除非另外定义,本文中使用的所有技术和科学术语具有本领域普通技术人员通常所理解的同样含义。参见例如Lackie,DICTIONARY OF CELLAND MOLECULAR BIOLOGY(《细胞和分子生物学词典》),埃尔斯威尔出版社(Elsevier)(2007年第4版);Green等,MOLECULARCLONING,A LABORATORY MANUAL(《分子克隆,实验室手册》)(第4版),冷泉港实验室出版社(冷泉港,纽约2012)。
术语“扩增组合物”或“扩增反应混合物”指包含用于扩增靶核酸的各种试剂的水性溶液。这些试剂包括酶、水性缓冲剂、盐、扩增引物、靶核酸和三磷酸核苷。如本文进一步讨论的,扩增反应混合物还可包含稳定剂和其它添加剂以优化效率和特异性。根据上下文,混合物可以是完全或是不完全的扩增组合物。
“聚合酶链反应”或“PCR”是指靶双链DNA的特定区段或子序列得以几何级数式扩增的一种方法。PCR是本领域技术人员所熟知的;参见例如,美国专利号4,683,195和4,683,202;和《PCR方案:方法和应用指南》,Innis等编,1990。示例性PCR反应条件一般包括两步或三步循环。两步循环具有变性步骤,之后是杂交/延伸步骤。三步循环包括变性步骤,之后是杂交步骤,之后是独立的延伸步骤。
“引物”指与靶核酸上的序列杂交并且用作核酸合成的起始点的多核苷酸序列。引物可以是各种长度的并且通常长度小于50个核苷酸,例如长度为12-30个核苷酸。可基于本领域技术人员已知的原理设计用于PCR的引物的长度和序列,参见例如Innis等(同上)。
“模板”指包含待扩增的多核苷酸、其侧接引物杂交位点的多核苷酸序列。因此,“靶模板”包含侧接5′引物和3′引物的杂交位点的靶多核苷酸序列。
本文所用的“核酸”表示DNA、RNA(单链或双链)、及其任意化学修饰。修饰包括但不限于,提供引入其它电荷、极化性、氢键、静电相互作用、与核酸配体碱基或核酸配体整体的连接点和作用点的化学基团的那些修饰。这类修饰包括但不限于,肽核酸(PNA)、磷酸二酯基团修饰(例如,硫代磷酸酯、甲基膦酸酯)、2′-位糖修饰、5-位嘧啶修饰、8-位嘌呤修饰、环外胺处的修饰、4-硫尿核苷的取代、5-溴或5-碘-尿嘧啶的取代、骨架修饰、甲基化、不常见的碱基配对组合如异碱基(isobases)、异胞苷和异胍(isoguanidine)等。核酸也可包含非天然碱基,如硝基吲哚。修饰还可包括3′和5′修饰,例如用荧光团(例如,量子点)或其它部分加帽。
术语“核酸”,“寡核苷酸”或“多核苷酸”可互换地是指可以对应于核糖核酸(RNA)或脱氧核糖核酸(DNA)聚合物或其类似物的单体的聚合物。这包括核苷酸的聚合物如RNA和DNA及其经修饰的形式、肽核酸(PNA)、锁核酸(LNATM)等。在某些应用中,该核酸可以是包含多种单体类型的聚合物,例如同时包含RNA和DNA亚基。
术语“多肽”、“肽”和“蛋白质”在本文中可互换使用,指氨基酸残基的聚合物。该术语适用于其中一个或多个氨基酸残基是相应天然产生氨基酸的人造化学模拟物的氨基酸聚合物,以及天然产生的氨基酸聚合物和非天然产生的氨基酸聚合物。
本文中,术语“氨基酸”指天然的和合成的氨基酸,以及作用方式类似于天然氨基酸的氨基酸类似物和氨基酸模拟物。天然氨基酸是由遗传密码编码的氨基酸以及后期修饰的氨基酸如羟基脯氨酸、γ-羧基谷氨酸和O-磷酸丝氨酸。氨基酸类似物指与天然产生的氨基酸具有相同基本化学结构的化合物,即碳原子与氢原子、羧基、氨基和R基结合,如高丝氨酸、正亮氨酸、甲硫氨酸亚砜、甲硫氨酸甲基锍。这种类似物具有修饰的R基(如正亮氨酸)或修饰的肽主链,但保留了与天然氨基酸相同的基本化学结构。氨基酸模拟物指结构不同于氨基酸通用化学结构但作用方式类似于天然氨基酸的化合物。
在本文中,氨基酸可用IUPAC-IUB生物化学命名委员会推荐的通用三字母符号或单字母符号表示。同样,核苷酸可由其公认的单字母代码表示。
“保守修饰的变体”适用于氨基酸和核酸序列。对于特定的核酸序列,保守修饰变体指编码相同或基本相同的氨基酸序列的核酸,或者当核酸不编码氨基酸序列时,指基本相同的序列。由于遗传密码的简并性,大量功能相同的核酸编码任何给定的蛋白质。例如,密码子GCA、GCC、GCG和GCU都编码氨基酸丙氨酸。因此,在密码子指定丙氨酸的每个位置,该密码子可以改变为所述的任何相应密码子而不改变编码的多肽。这种核酸变异是“沉默变异”,其是保守修饰变异的一种。本文编码多肽的每种核酸序列也描述该核酸的每种可能的沉默变异。本领域技术人员应认识到,核酸中的每个密码子(除了AUG,其通常是甲硫氨酸的唯一密码子,和TGG,其通常是色氨酸的唯一密码子)均可以被修饰以产生功能相同的分子。因此,在所述的各序列中隐含了编码多肽的各核酸沉默变异。
至于氨基酸序列,本领域技术人员应认识到,核酸、肽、多肽或蛋白质序列的一些个体取代、缺失或添加(其改变、添加或删除编码序列中的单个氨基酸或少量氨基酸)是“保守修饰的变体”,其中所述改变导致被化学上相似的氨基酸取代的氨基酸取代。提供功能上相似氨基酸的保守取代表是本领域熟知的。此类保守修饰的变体是本发明的多态性变体、种间同源物和等位基因的补充且并不排除它们。
术语“编码”指编码一种或多种氨基酸的多核苷酸序列。该术语无需起始或终止密码子。氨基酸序列可编码于多核苷酸序列提供的六种不同的阅读框中任一种中。
术语“启动子”指定位于转录起始上游和/或下游且涉及识别和结合RNA聚合酶和其它蛋白质以起始转录的区域或序列。
“载体”指多核苷酸,其独立于宿主染色体时能够在宿主生物体中复制。优选的载体包括质粒且通常具有复制起始点。载体可包括,例如,转录和翻译终止子、转录和翻译起始序列和用于调控特定核酸表达的启动子。本发明所述的任何多核苷酸都可包含在载体内。
如本文所用,“DNA聚合酶”或“聚合酶”是指执行模板指导的DNA合成的酶。该术语同时包括全长多肽和具有聚合酶活性的结构域。DNA聚合酶是本领域技术人员熟知的,包括但不限于分离或衍生自激烈火球菌(Pyrococcus furiosus)、滨海嗜热球菌(Thermococcuslitoralis)、嗜热脂肪芽孢杆菌(Bacillus stearothermophilus)和海栖热袍菌(Thermotoga maritime)的DNA聚合酶或其修饰版本。
当如下述比对最大对应性时,如果在两条序列中核苷酸或氨基酸残基的序列分别是相同的,两条核酸序列或多肽被称为“相同的”。在两条或更多条核酸或多肽序列内容中的术语“相同的”或“相同性”百分比指就比较窗的最大对应性进行比较和比对时,相同或有特定百分数的相同氨基酸残基或核苷酸的两条或更多条序列或子序列,如使用下列序列比较算法之一或通过手工比对和目测测量。序列相同性百分比涉及蛋白质和肽使用时,认为不同的残基位置通常由于保守氨基酸取代而不同,其中氨基酸残基被具有相似化学性质(如电荷或疏水性)的其他氨基酸残基取代,因此不改变分子的功能性质。当序列由于保守取代而不同时,序列相同性百分比可上调以根据该取代的保守性质校正。进行该调整的方法为本领域技术人员公知。通常其包括将保守取代作为部分评分而不是完全错配,从而增加序列相同性百分比。因此例如,相同氨基酸得分为1,非保守取代得分为0,保守取代得分为0-1。保守取代的评分按照,例如Meyers和Miller的算法,Computer Applic.Biol.Sci.4:11-17(1988),例如,如在程序PC/GENE(美国加利福尼亚州芒廷维尤的智慧遗传公司(Intelligenetics,Mountain View,California,USA))中执行的进行计算。
如果就比较窗口上的最大对应性而言,这些序列有特定百分数的核苷酸或氨基酸残基相同(例如在特定区域上或整个指定序列(如果区域不特定)上至少60%、70%、75%、80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%相同),则序列彼此间“基本相同”。
为了序列比较,一般将一个序列用作与测试序列比较的参比序列。当使用序列比较算法时,将测试和参比序列输入计算机,如果需要,指定子序列坐标,并指定序列算法程序参数。可使用默认的程序参数,或者可指定另外的参数。然后,序列比较算法基于程序参数计算测试序列相对于参比序列的序列相同性百分比。
如本文所用,“比较窗口”包括对于选自20至600,通常约50至约200,更通常约100至约150个的多个邻接位置中的任何一个的区段的参考,其中,在两个序列最佳比对后,可以将序列与连续位置的相同数目的参比序列进行比较。
可使用BLAST 2.0算法确定百分比序列相同性和序列相似性,其在Altschul等(J.Mol.Biol.215:403-10,1990)中描述。进行BLAST 2.0分析的软件可从国家生物技术信息中心(National Center for Biotechnology Information)公开获得(http://ncbi.nlm.nih.gov/)。此算法包括:首先通过鉴定查询序列中长度为W的短字来鉴定高评分序列对(HSP),与数据库序列中长度相同的字比对时它们能匹配或满足一些正值的阈值评分T。T称为相邻字评分阈值(Altschul等,同上)。这些初始相邻字命中(word hit)用作启动搜索的种子,以便找到含有它们的较长HSP。只要可提高累积比对评分,所述字命中在两个方向上沿各序列延伸。出现以下情况时中止字命中在各个方向上的延伸:累积比对评分比其最大获得值降低X;由于一个或多个负评分残基比对的累积,累积评分变为零或零以下;或者达到任一序列的末端。BLAST算法参数W、T和X确定该比对的灵敏度和速度。BLAST程序使用的默认值为:字长(W)11,BLOSUM62评分矩阵(参见Henikoff和Henikoff,Proc.Natl.Acad.Sci.USA 89:10915(1989))比对(B)50,期望值(E)10,M=5,N=-4,以及比较两条链。
BLAST算法也对两条序列间的相似性进行统计学分析(参见例如,Karlin和Altschul,Proc.Nat’l.Acad.Sci.USA 90:5873-5787(1993))。BLAST算法提供的一种相似性度量是最小概率和(P(N)),它表明两条核苷酸或氨基酸序列之间偶尔发生匹配的概率。例如,如果测试核酸与参比核酸比较时的最小概率和小于约0.2,更优选小于约0.01,最优选小于约0.001,那么认为该核酸与参比序列相似。
在本说明书和所附权利要求书中所用的单数形式“一个”、“一种”和“该”包括多个指示物,除非上下文中有明显的表示。如本文中所用,术语“约”是指所列的数字以及所列数字10%范围内的任何值。因此,“约5”是指在4.5-5.5之间的任何值,包括4.5和5.5。
II.聚合酶
在一个实施方式中,突变A型DNA聚合酶包含至少三个突变,其对应于野生型水生栖热菌(Taq)DNA聚合酶的一个或多个氨基酸残基551、788和798(或与之对齐)。与野生型DNA聚合酶相比,突变聚合酶对聚合活性抑制剂具有更高的抗性,即,在一种或多种抑制剂的存在下,出现可接受水平的DNA聚合或所需产物的正确扩增。如本文所用,如果突变DNA聚合酶具有通过定量PCR获得的约0.5或更大的ΔΔ定量循环值(或ΔΔCq值),则其对抑制具有抗性。在一些实施方式中,突变体的ΔΔCq值为约1至约5。在一些实施方式中,突变体的ΔΔCq值为至少约5。如本文所用,Cq值为与任意阈值相交的(经基线校正的)扩增曲线的定量循环值(即作为循环数的函数绘制的相对荧光单位)。ΔCq值定义为:
ΔCq值=Cq值存在-Cq值缺失 (1)
其中Cq值存在是抑制剂存在下的Cq值,而Cq值缺失是抑制剂缺失时的Cq值。
ΔΔCq值突变定义为:
ΔΔCq值突变=ΔCq值参考-ΔCq值突变 (2)
其中ΔCq值参考是参考A型DNA聚合酶的ΔCq值,并且ΔCq值突变是突变体的ΔCq值。在一些实施方式中,参考A型DNA聚合酶是野生型Taq聚合酶。在一些实施方式中,参考A型DNA聚合酶是非野生型Taq聚合酶。在任一种情况下,参考聚合酶在其他方面均与突变聚合酶相同,不同之处在于参考将在突变位置具有野生型氨基酸(例如,包括但不限于D551,V788和A798)。
在一些实施方式中,突变A型DNA聚合酶在氨基酸残基52、99、109、128、154、259、268和739处包含一个或多个其他突变。图1列出了与野生型Taq DNA聚合酶(SEQ ID NO:8)相比,这种突变A型DNA聚合酶的七个实例(SEQ ID NO:1-7)。对应于野生型Taq DNA聚合酶的氨基酸残基52、99、109、128、154、259、268、551、739、788和/或798的突变可位于图1中。位置名称不指示所讨论氨基酸的数字位置,而是指野生型Taq DNA聚合酶中出现最大比对的氨基酸时的位置。
在一些实施方式中,突变Taq DNA聚合酶包含D551R,V788L和A798E处的突变。在一些实施方式中,突变A型DNA聚合酶在L52A,I99M,A109E,K128I,H154A,A259R,R268G和/或S739R处包含一个或多个其他突变。在某些实施方式中,突变A型DNA聚合酶包含SEQ ID NO:1,SEQ ID NO:2,SEQ ID NO:3,SEQ ID NO:4,SEQ ID NO:5,SEQ ID NO:6或SEQ ID NO:7。下面的表1列出了七个示例性的突变A型DNA聚合酶(即SEQ ID NO:1-7)的氨基酸位置和相应的突变。
表1
Figure BDA0002587971730000091
Figure BDA0002587971730000101
突变A型DNA聚合酶对血液样品中的抑制剂有抗性,这些抑制剂包括但不限于乳铁蛋白,免疫球蛋白G(IgG),血浆和蛋白酶。在一些实施方式中,突变A型DNA聚合酶对血液样品中的抗凝剂,例如肝素有抗性。对血液样品中存在的抑制剂(包括添加到血液中的抗凝剂等抑制剂)的抗性与医学和法医分析密切相关。
在一些实施方式中,突变A型DNA聚合酶比野生型A型DNA聚合酶更热稳定。如本文所用,热稳定是指在给定温度和孵育时间下孵育前后,通过qPCR测定的Cq值无变化(即增加)的聚合酶(即,ΔCq值=热处理后的Cq-热处理前的Cq=0)。在一些实施方式中,突变A型DNA聚合酶在94℃或更高温度下热稳定至少15秒。在一些实施方式中,突变A型DNA聚合酶在98℃下热稳定至少15分钟。
实施例中描述的突变DNA聚合酶是野生型Taq DNA聚合酶的突变形式,其具有改变的特征,从而为突变聚合酶提供了改善的抑制剂抗性。然而,应理解,突变聚合酶不限于本文讨论的示例性实施方式。例如,包括不同于Taq DNA聚合酶的聚合酶的突变体,例如任何A型家族DNA聚合酶的突变体。这些突变体可以是聚合酶的突变体,包括但不限于来自栖热菌属的那些。A型DNA聚合酶显示出高水平的序列相同性和保守性,并且可以识别一种特定的A型DNA聚合酶中对应于另一种A型DNA聚合酶的残基的残基。因此,本文中提及的野生型TaqDNA聚合酶中的特定突变可以与其他聚合酶中的相应突变相关。
图1显示了来自水生栖热菌(Thermus aquaticus)的野生型A型Taq DNA聚合酶的一级氨基酸序列与突变A型DNA聚合酶SEQ ID NO:1-7的比对。如图1所示,野生型和突变A型DNA聚合酶的多个区域高度保守,而其他区域则可变。除了在本文中具体鉴定和讨论的突变以外,还可以在A型DNA聚合酶的可变区中进行突变,而不改变或基本上不改变突变酶的聚合酶活性。同样,可以在保守残基处进行保守突变而不改变或基本上不改变突变酶的聚合酶活性。使用氨基酸的结构数据和已知的物理特性,本领域技术人员可以使酶,例如本文所述的DNA聚合酶突变,而不改变或基本不改变酶的基本酶促特性。
在样品中存在抑制剂的情况下,本文所述的突变DNA聚合酶多肽的氨基酸序列可以变化,而不破坏在本文所述的引物延伸反应条件和/或PCR反应条件下催化DNA复制的能力。例如,突变体可包含一个或多个(例如1-10个)保守性氨基酸取代。“保守性氨基酸取代”是其中一个氨基酸残基被具有相似侧链的另一个氨基酸残基替代的情况。本领域已定义具有带相似侧链的氨基酸残基家族。这些家族包括:具有碱性侧链的氨基酸(如赖氨酸、精氨酸、组氨酸)、具有酸性侧链的氨基酸(如天冬氨酸、谷氨酸)、具有不带电极性侧链的氨基酸(如甘氨酸、天冬酰胺、谷氨酰胺、丝氨酸、苏氨酸、酪氨酸、半胱氨酸)、具有非极性侧链的氨基酸(如丙氨酸、缬氨酸、亮氨酸、异亮氨酸、脯氨酸、苯丙氨酸、甲硫氨酸、色氨酸)、具有β-分支侧链的氨基酸(如苏氨酸、缬氨酸、异亮氨酸)和具有芳族侧链的氨基酸(如酪氨酸、苯丙氨酸、色氨酸、组氨酸)。因此,可以用来自相同侧链家族的另一个氨基酸残基替换SEQ IDNO:1-7中的预测的非必需氨基酸残基。可以通过包括但不限于定点诱变,基因改组和/或定向进化的过程沿着全部或部分序列随机引入突变。
还提供了每个突变体的多肽或多肽衍生物的变体,例如具有一个或多个点突变,***,缺失,截短,融合蛋白或其组合的蛋白质。功能等同物在本文所述的PCR条件下(例如,含有含聚合酶抑制剂的血液样品的PCR反应混合物中并占混合物的至少1%(例如,2%,2.5%,5%,10%,20%,25%,30%,35%,40%,45%,或50%)v/v)基本上保留了突变DNA聚合酶的活性。在一些实施方式中,分离的多肽可包含SEQ ID NO:1-7中的任何一个或其功能片段或等同物。通常,功能等同物分别与SEQ ID NO:1-7中的任一个至少70%(例如,介于70%和100%之间的任何数字,包括70%,75%,80%,85%,90%,91%,92%,93%,94%,95%,96%,97%,98%和99%)相同。
如本文所述的多肽可以是重组多肽。为了制备重组多肽,可以将编码其的核酸与编码融合伴侣的另一核酸连接,例如谷胱甘肽-s-转移酶(GST),6x-His表位标签(SEQ IDNO:16)或M13基因3蛋白质。所得的融合核酸在合适的宿主细胞中表达可以通过本领域已知的方法分离的融合蛋白。分离的融合蛋白可以进一步处理,例如通过酶消化,以去除融合伴侣并获得本文所述的重组多肽。或者,多肽可以化学合成(参见例如,Creighton,“蛋白质:结构和分子原理(Proteins:Structures and Molecular Principles)”,W.H.弗里曼公司(W.H.Freeman&Co.),纽约,1983),或通过本文所述的重组DNA技术产生。
本文所述的突变DNA聚合酶可以纯化或分离的形式提供,或者可以是组合物的一部分。当处于组合物中时,首先将突变DNA聚合酶纯化至约80%,90%,95%或99%或更高的纯度。可按照本领域的标准程序纯化突变聚合酶,例如,通过硫酸铵沉淀,层析,凝胶电泳等(一般参见R.Scopes,“蛋白质纯化”(Protein Purification),Springer-Verlag,N.Y.(1982),Deutscher,《酶学方法》(Methods in Enzymology)卷182:《蛋白质纯化指南》(Guide to Protein Purification),学术出版公司,纽约(1990))。本文所述的组合物可以是所需的任何类型的组合物,但是通常是适用于例如通过使用PCR技术扩增靶核酸的水性组合物。这样,组合物通常包含除突变DNA聚合酶以外的至少一种物质,例如水,甘油或另一种稳定剂,水性缓冲剂,水性盐缓冲剂,金属离子(例如二价金属,例如镁)。在示例性实施方式中,组合物包含PCR反应中通常存在的溶剂,盐,缓冲剂,核苷酸和其他试剂中的一些或全部。因此,在一些实施方式中,组合物包含金属离子(例如,镁盐,例如氯化镁或硫酸镁),一种或多种三磷酸核苷,一种或多种核酸引物或探针,一种或多种其他核酸聚合酶或具有所需活性的片段,一种或多种聚合检测剂(例如,特异性或非特异性染料或荧光分子)和/或用于扩增或测序的一种或多种核酸模板。其他示例性物质包括但不限于去污剂,DMSO,DMF,明胶,甘油,甜菜碱,亚精胺,T4基因32蛋白,大肠杆菌SSB,BSA和硫酸铵。
III.核酸,载体和宿主细胞
还提供了编码本文所述的任何突变DNA聚合酶的核酸。可以使用重组遗传学领域中的常规技术获得编码突变DNA聚合酶的核酸。
还提供了具有本文所述的一个或多个核苷酸序列的载体。载体指能够运输与之相连的另一核酸的核酸分子。载体能够自主复制或整合到宿主DNA中。示例性载体包括但不限于质粒,粘粒或病毒载体。载体可包含适合于核酸在宿主细胞中表达的形式的核酸。在一些实施方式中,载体包括可操作地连接至要表达的核酸序列的一个或多个调控序列。“调控序列”包括启动子,增强子和其他表达控制元件(例如,聚腺苷酸化信号)。调控序列包括指导核苷酸序列组成型表达的序列以及可诱导的调控序列。表达载体的设计可取决于诸如要转化,转染或感染的宿主细胞的选择以及所需蛋白质表达水平等因素。合适的载体和启动子是本领域技术人员已知的,并且是可商购的。Sambrook等也描述了用于原核和真核宿主的合适的克隆和表达载体(2001,分子克隆:实验室手册(Molecular Cloning:A LaboratoryManual),冷泉港出版社)。
表达载体的实例包括但不限于染色体,非染色体和合成的DNA序列,例如猿猴病毒40(SV40)的衍生物,细菌质粒,噬菌体DNA,杆状病毒,酵母质粒,衍生自质粒和噬菌体DNA组合的载体,病毒DNA(例如牛痘,腺病毒,鸡痘病毒和伪狂犬病)。但是,可以使用任何其他载体,只要它在宿主中可复制和可行。可以通过多种方法将合适的核酸序列***载体。通常,可以通过本领域已知的方法将编码本文所述多肽之一的核酸序列***合适的限制性核酸内切酶位点。
表达载体还可包含用于翻译起始的核糖体结合位点和转录终止子。载体可以包括用于扩增表达的合适序列。另外,表达载体优选包含一种或多种选择标志物基因,以提供表型性状,用于选择转化的宿主细胞(例如,对真核细胞培养物的二氢叶酸还原酶或新霉素抗性;在大肠杆菌中的四环素或氨苄青霉素抗性)。
包含本文所述的合适核酸序列以及合适的启动子或控制序列的载体可以用于转化,转染或感染合适的宿主以允许宿主表达本文所述的多肽(例如,SEQ ID NO:1-7)。合适的表达宿主的实例包括细菌细胞(例如,大肠杆菌,链霉菌,鼠伤寒沙门氏菌),真菌细胞(酵母),昆虫细胞(例如,果蝇和草地贪夜蛾(Sf9)),动物细胞(例如,CHO,COS,和HEK293),腺病毒和植物细胞。合适的宿主的选择在本领域技术人员的范围内。在一些实施方式中,提供了通过用具有编码所述多肽之一的核苷酸序列的表达载体转化,转染或感染宿主细胞来产生本文所述的突变DNA聚合酶多肽的方法。然后在合适的条件下培养宿主细胞,其允许多肽的表达。
IV.方法和用途
本文所述的突变A型DNA聚合酶可用于多种方法中以扩增靶核酸。例如,突变A型DNA聚合酶和包含此类突变聚合酶的组合物可以用于引物延伸方法或用于从引物或引物组和核酸模板聚合核酸的方法中。在一个实施方式中,一种扩增靶核酸的方法包括使疑似含有靶核酸的测试样品与本文所述的任一突变聚合酶,与靶核酸特异性结合的至少一种引物以及核苷酸接触以形成混合物或组合物。混合物可以手动或自动形成。该方法的下一步包括使用靶核酸的序列作为掺入核苷酸的模板,在允许至少一种引物通过聚合酶延伸(或聚合)的条件下孵育混合物。
多种核酸可以进行复制,扩增或测序。因此,该方法不受靶核酸,其序列或长度的限制。应当理解,在需要扩增(例如PCR)的情况下,应当使用两种具有不同序列并且对靶核酸的相对链上的两种不同序列具有特异性的引物。另外,使结合的物质暴露于允许聚合的条件的步骤可以是任何允许聚合的作用。许多适合聚合的条件是本领域已知的,并且本领域技术人员可以根据情况需要选择任何合适的条件,而无需过度或过量的实验。要考虑的参数包括但不限于盐浓度,金属离子或螯合剂浓度,缓冲剂浓度和特性,去污剂和有机溶剂的存在与否,聚合酶或其他酶的浓度,核苷酸或修饰核苷酸的存在或浓度,聚合抑制剂或终止剂的存在或浓度,用于检测聚合产物的探针或染料的存在或浓度,温度和暴露时间。在一些实施方式中,允许来自引物的核酸聚合的条件是PCR反应的条件。
聚合酶可有利地用于PCR反应的任何变化或类型中,以扩增核酸,包括DNA和RNA扩增。为了扩增RNA模板(例如,mRNA或微小RNA),可以使用RNA依赖性DNA聚合酶(例如,逆转录酶;RT)来制备与RNA模板互补的DNA链,并且本发明的DNA聚合酶可以用于扩增DNA互补链。可以使用本文所述的组合物进行的聚合酶链反应包括但不限于逆转录PCR(RT-PCR),定量PCR(qPCR)和数字液滴PCR(ddPCR)。
在一些实施方式中,在该方法中使用具有不同序列的两种或更多种引物。例如,在一些实施方式中,使用两种引物。一种引物特异性结合模板DNA的一条链,另一种引物结合模板DNA的另一条链,从而产生双链聚合产物。在一些实施方式中,一种引物对存在于单链RNA模板上的序列例如mRNA具有特异性。来自第一引物的RNA的第一互补链的聚合提供了第二引物的模板。在第一聚合反应之后,第一引物可以从模板RNA或DNA互补物引发聚合反应。对靶核酸(包括靶的互补链,其中靶是单链的)具有序列特异性的一种或多种核酸探针可以包括在检测扩增的靶核酸的方法中。
诸如qPCR和ddPCR之类的PCR方法包括探针,染料或其他允许检测聚合(例如扩增)产物的物质。因此,该方法可以包括在聚合反应中包括允许检测聚合产物的物质的步骤。该方法还可以包括一个或多个阳性或阴性对照反应,以确定该方法或特定方法步骤是否已成功进行。
V.试剂盒
还提供了根据本文所述方法扩增核酸的试剂盒。试剂盒包含一种或多种本文所述的突变DNA聚合酶。该试剂盒还可包含用于进行扩增反应的其他组分。其他组分可包括但不限于缓冲剂(1x或浓缩形式),金属离子(例如Mg2+),核苷酸,对对照核酸或靶核酸特异的引物,对对照核酸或靶核酸特异性的探针,去污剂和/或用于检测聚合产物的检测剂(例如一种或多种染料或一种或多种荧光分子)。在一些实施方式中,试剂盒还包括用来进行本文所述方法的说明。
VI.实施例
实施例1:抑制剂耐受性
本实施例比较了突变Taq DNA聚合酶SEQ ID NO:1-7与野生型Taq DNA聚合酶的PCR抑制剂耐受性。
包含20mM Tris-HCl(pH 8.4),50mM KCl,0.02%(v/v)曲通-100、10mM MgCl2、1mMdNTP(各1mM),各0.2μM的引物1(GAAGGTGAAGGGTCGGAGTC(SEQ ID NO:17)和引物2(GAAGATGGTGATGGGATTTC(SEQ ID NO:18),1ng 226bp的人基因组DNA,0.5x SYBR Green染料,抑制剂X和1.7u聚合酶(总体积为20μL)进行以下热循环条件:在95℃下2分钟,然后进行40个循环的10s 95℃,45s 60℃。测试的抑制剂X浓度如下:
·乳铁蛋白(西格玛奥德里奇(Sigma-Aldrich),L9507-10MG):0ng/ul,5ng/ul,10ng/ul,15ng/ul,20ng/ul,25ng/ul,30ng/ul(w/v);
·IgG(西格玛奥德里奇,I4506):0ng/ul,10ng/ul,20ng/ul,30ng/ul,30ng/ul,40ng/ul,50ng/ul,60ng/ul,(w/v);
·血浆(西格玛奥德里奇,P9523):0%,1%,2%,3%,5%,6%,8%,10%(v/v)
·肝素(西格玛奥德里奇,H3149):0,0.001,0.002,0.005,0.01,0.015,0.02,0.03,0.05UPS肝素(每20ul的PCR反应)。
实时qPCR在Bio-Rad CFX96实时PCR检测***上进行。结果示于下表2。如表2所示,“+”表示突变体的ΔΔCq值是1-5。“++”表示突变体的ΔΔCq值大于5。“-”表示ΔΔCq值约为零(即ΔCq值与野生型Taq聚合酶相似,或者突变和野生型Taq聚合酶的抑制剂耐受性没有差异)。
表2
Figure BDA0002587971730000161
Figure BDA0002587971730000171
表2中的结果表明,所有七个突变体均表现出对IgG和乳铁蛋白的耐受性。除5号突变体外,其他所有突变体均对血浆具有抗性,而1号突变体和3-6号突变体对肝素具有抗性。
实施例2:热稳定性
本实施例比较了突变Taq DNA聚合酶SEQ ID NO:1-7与野生型Taq DNA聚合酶的热稳定性。
包含20mM Tris-HCl(pH 8.4),50mM KCl,0.02%(v/v)曲二通X-100、10mM MgCl2、1mM dNTP(各1mM),各0.2μM的引物1(GAAGGTGAAGGGTCGGAGTC(SEQ ID NO:17)和引物2(GAAGATGGTGATGGGATTTC(SEQ ID NO:18),1ng 226bp的人基因组DNA,0.5x SYBR Green染料,1.7u聚合酶(总体积为20μL)进行以下热循环条件:在98℃下15分钟,然后进行40个循环的98℃下10秒,和60℃下45秒。实时定量PCR在Bio-Rad CFX96实时PCR检测***上进行。结果示于下表3。在表3中,“+”表示突变Taq DNA聚合酶在98℃下加热15分钟时的ΔCq=0(即,热处理后的Cq-热处理前的Cq=0),而在这种加热条件之后,野生型Taq DNA聚合酶的ΔCq大于零。“-”表示在这种加热条件后,突变Taq DNA聚合酶的ΔCq与野生型Taq聚合酶的ΔCq相似。
表3
Figure BDA0002587971730000181
结果表明,在测试的突变体中,3-5和7号突变体在98℃下热稳定15分钟。
本说明书中引用的所有专利、专利申请和其它公开的参考材料都通过引用全文结合入本文中。
序列表
SEQ ID NO:1-8示于图1。
突变DNA聚合酶1号的核苷酸序列表:SEQ ID#9
Figure BDA0002587971730000182
Figure BDA0002587971730000191
Figure BDA0002587971730000201
突变DNA聚合酶2号的核苷酸序列表:SEQ ID#10
Figure BDA0002587971730000202
Figure BDA0002587971730000211
Figure BDA0002587971730000221
突变DNA聚合酶3号的核苷酸序列表:SEQ ID#11
Figure BDA0002587971730000222
Figure BDA0002587971730000231
Figure BDA0002587971730000241
突变DNA聚合酶4号的核苷酸序列表:SEQ ID#12
Figure BDA0002587971730000242
Figure BDA0002587971730000251
Figure BDA0002587971730000261
突变DNA聚合酶5号的核苷酸序列表:SEQ ID#13
Figure BDA0002587971730000262
Figure BDA0002587971730000271
Figure BDA0002587971730000281
突变DNA聚合酶6号的核苷酸序列表:SEQ ID#14
Figure BDA0002587971730000282
Figure BDA0002587971730000291
Figure BDA0002587971730000301
突变DNA聚合酶7号的核苷酸序列表:SEQ ID#15
Figure BDA0002587971730000302
Figure BDA0002587971730000311
Figure BDA0002587971730000321
序列表
<110> 生物辐射实验室股份有限公司(BIO-RAD LABORATORIES, INC.)
<120> 突变DNA聚合酶
<130> 094260-1116788 (115810PC)
<140>
<141>
<150> 62/619,394
<151> 2018-01-19
<160> 18
<170> PatentIn version 3.5
<210> 1
<211> 830
<212> PRT
<213> 人工序列
<220>
<223> 人工序列说明:合成多肽
<400> 1
Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu Val Asp Gly
1 5 10 15
His His Leu Ala Tyr Arg Asn Phe Phe Thr Leu Lys Gly Pro Thr Thr
20 25 30
Ser Arg Gly Glu Pro Val Gln Gly Val Tyr Gly Phe Ala Lys Ser Leu
35 40 45
Ala Lys Ala Leu Lys Glu Asp Gly Asp Val Val Ile Val Val Phe Asp
50 55 60
Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Ala Tyr Lys Ala
65 70 75 80
Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu Ala Leu Met
85 90 95
Lys Glu Leu Val Asp Leu Leu Gly Leu Glu Arg Leu Glu Val Pro Gly
100 105 110
Phe Glu Ala Asp Asp Val Leu Ala Ala Leu Ala Lys Ile Ala Glu Arg
115 120 125
Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Arg Asp Leu Phe Gln
130 135 140
Leu Leu Ser Asp Arg Ile Ala Leu Leu His Pro Glu Gly His Leu Ile
145 150 155 160
Thr Pro Gly Trp Leu Trp Glu Arg Tyr Gly Leu Arg Pro Glu Gln Trp
165 170 175
Val Asp Phe Arg Ala Leu Ala Gly Asp Pro Ser Asp Asn Ile Pro Gly
180 185 190
Val Lys Gly Ile Ser Glu Lys Thr Ala Leu Lys Leu Leu Lys Glu Trp
195 200 205
Gly Ser Leu Glu Asn Ile Gln Lys Asn Leu Ala Gln Val Lys Pro Glu
210 215 220
Arg Val Arg Glu Ala Ile Arg Asn Asn Leu Asp Lys Leu Gln Met Ser
225 230 235 240
Leu Glu Leu Ser Arg Leu Arg Thr Asp Leu Pro Leu Glu Val Asp Phe
245 250 255
Arg Arg Arg Arg Glu Pro Asp Arg Glu Gly Leu Arg Ala Phe Leu Glu
260 265 270
Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu Glu Ser
275 280 285
Pro Lys Ala Leu Glu Glu Ala Leu Trp Pro Pro Pro Glu Gly Ala Phe
290 295 300
Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp Leu Leu
305 310 315 320
Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro Glu Pro
325 330 335
Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu Ala Lys
340 345 350
Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro Pro Gly
355 360 365
Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn Thr Thr
370 375 380
Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu Glu Ala
385 390 395 400
Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asp Leu Trp Gly
405 410 415
Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu Val Glu
420 425 430
Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly Val Arg
435 440 445
Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala Glu Glu
450 455 460
Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His Pro Phe
465 470 475 480
Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp Glu Leu
485 490 495
Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg Ser Thr
500 505 510
Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile Val Glu
515 520 525
Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr Tyr Ile
530 535 540
Asp Pro Leu Pro Arg Leu Val His Pro Lys Thr Gly Arg Leu His Thr
545 550 555 560
Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp
565 570 575
Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln Arg Ile
580 585 590
Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala Leu Asp
595 600 605
Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly Asp Glu
610 615 620
Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr Glu Thr
625 630 635 640
Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro Leu Met
645 650 655
Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly Met Ser
660 665 670
Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu Ala Gln
675 680 685
Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg Ala Trp
690 695 700
Ile Ala His Thr Leu Glu Glu Gly Arg Lys Lys Gly Tyr Val Glu Thr
705 710 715 720
Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn Ala Arg Val Lys
725 730 735
Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Ala Val Gln
740 745 750
Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu Phe Pro
755 760 765
Arg Leu Pro Glu Val Gly Ala Arg Met Leu Leu Gln Val His Asp Glu
770 775 780
Leu Leu Leu Glu Ala Pro Lys Glu Arg Ala Glu Glu Ala Ala Ala Leu
785 790 795 800
Ala Lys Glu Val Met Glu Gly Val Trp Pro Leu Ala Val Pro Leu Glu
805 810 815
Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Gly
820 825 830
<210> 2
<211> 830
<212> PRT
<213> 人工序列
<220>
<223> 人工序列说明:合成多肽
<400> 2
Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu Val Asp Gly
1 5 10 15
His His Leu Ala Tyr Arg Asn Phe Phe Thr Leu Lys Gly Leu Thr Thr
20 25 30
Ser Arg Gly Glu Pro Val Gln Gly Val Tyr Gly Phe Ala Lys Ser Leu
35 40 45
Ala Lys Ala Leu Lys Glu Asp Gly Asp Val Val Ile Val Val Phe Asp
50 55 60
Ala Glu Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Ala Tyr Lys Ala
65 70 75 80
Gly Arg Ala Pro Thr Arg Glu Asp Phe Pro Arg Gln Leu Ala Leu Met
85 90 95
Lys Glu Leu Val Asp Leu Leu Gly Leu Glu Arg Leu Glu Val Pro Gly
100 105 110
Phe Glu Ala Asp Asp Val Leu Ala Ala Leu Ala Lys Ile Ala Glu Arg
115 120 125
Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Arg Asp Leu Phe Gln
130 135 140
Leu Leu Ser Asp Arg Ile Ala Val Leu His Pro Glu Gly His Leu Ile
145 150 155 160
Thr Pro Gly Trp Leu Trp Glu Arg Tyr Gly Leu Arg Pro Glu Gln Trp
165 170 175
Val Asp Phe Arg Ala Leu Ala Gly Asp Pro Ser Asp Asn Ile Pro Gly
180 185 190
Val Lys Gly Ile Ser Glu Lys Thr Ala Leu Lys Leu Leu Lys Glu Trp
195 200 205
Gly Ser Leu Glu Asn Ile Gln Lys Asn Leu Ala Gln Val Lys Pro Glu
210 215 220
Arg Val Arg Glu Ala Ile Arg Asn Asn Leu Asp Lys Leu Gln Met Ser
225 230 235 240
Leu Glu Leu Ser Arg Leu Arg Thr Asp Leu Pro Leu Glu Val Asp Phe
245 250 255
Arg Arg Arg Arg Lys Pro Asp Arg Glu Gly Leu Arg Ala Phe Met Glu
260 265 270
Arg Leu Glu Phe Asp Ser Leu Leu His Glu Phe Gly Leu Leu Glu Ser
275 280 285
Pro Lys Ala Leu Glu Glu Ala Leu Trp Pro Pro Pro Glu Gly Ala Phe
290 295 300
Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp Leu Leu
305 310 315 320
Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro Glu Pro
325 330 335
Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu Ala Lys
340 345 350
Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro Pro Gly
355 360 365
Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn Thr Thr
370 375 380
Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu Glu Ala
385 390 395 400
Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asp Leu Trp Gly
405 410 415
Arg Leu Glu Glu Glu Glu Arg Leu Leu Trp Leu Tyr His Glu Val Glu
420 425 430
Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly Val Arg
435 440 445
Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala Glu Glu
450 455 460
Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His Pro Phe
465 470 475 480
Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp Glu Leu
485 490 495
Gly Leu Pro Pro Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg Ser Thr
500 505 510
Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile Val Glu
515 520 525
Lys Ile Leu Gln Tyr Arg Glu Leu Ala Lys Leu Lys Ser Thr Tyr Ile
530 535 540
Asp Pro Leu Pro Arg Leu Val His Pro Lys Thr Gly Arg Leu His Thr
545 550 555 560
Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp
565 570 575
Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln Arg Ile
580 585 590
Arg Lys Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala Leu Asp
595 600 605
Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly Asp Glu
610 615 620
Asn Leu Ile Arg Val Phe Arg Glu Gly Lys Asp Ile His Thr Glu Thr
625 630 635 640
Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro Leu Met
645 650 655
Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly Met Ser
660 665 670
Ala His Arg Leu Ser Gln Glu Leu Ser Ile Pro Tyr Glu Glu Ala Ala
675 680 685
Ala Phe Ile Glu Arg Tyr Phe Gln Arg Phe Pro Gln Val Arg Ala Trp
690 695 700
Ile Ala His Thr Leu Glu Glu Gly Arg Lys Lys Gly Tyr Val Glu Thr
705 710 715 720
Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn Ala Arg Val Lys
725 730 735
Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Ala Val Gln
740 745 750
Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu Phe Pro
755 760 765
Arg Leu Arg Pro Leu Gly Val Arg Met Leu Leu Gln Val His Asp Glu
770 775 780
Leu Leu Leu Glu Ala Pro Lys Glu Arg Ala Glu Glu Ala Ala Ala Leu
785 790 795 800
Ala Lys Glu Val Met Glu Gly Val Trp Pro Leu Ala Val Pro Leu Glu
805 810 815
Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Gly
820 825 830
<210> 3
<211> 830
<212> PRT
<213> 人工序列
<220>
<223> 人工序列说明:合成多肽
<400> 3
Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu Val Asp Gly
1 5 10 15
His His Leu Ala Tyr Arg Asn Phe Phe Thr Leu Arg Gly Leu Thr Thr
20 25 30
Ser Arg Gly Glu Pro Val Gln Gly Val Tyr Gly Phe Ala Lys Ser Leu
35 40 45
Ala Lys Ala Leu Lys Glu Asp Gly Asp Val Val Ile Val Val Phe Asp
50 55 60
Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Ala Tyr Lys Ala
65 70 75 80
Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu Ala Leu Met
85 90 95
Lys Glu Leu Val Asp Leu Leu Gly Leu Glu Arg Leu Glu Val Pro Gly
100 105 110
Phe Glu Ala Asp Asp Val Leu Ala Ala Leu Ala Lys Ile Ala Glu Arg
115 120 125
Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Arg Asp Leu Phe Gln
130 135 140
Leu Leu Ser Asp Arg Ile Ala Val Leu His Pro Glu Gly His Leu Ile
145 150 155 160
Thr Pro Gly Trp Leu Trp Glu Arg Tyr Gly Leu Arg Pro Glu Gln Trp
165 170 175
Val Asp Phe Arg Ala Leu Thr Gly Asp Pro Ser Asp Asn Ile Pro Gly
180 185 190
Val Lys Gly Ile Gly Glu Lys Thr Ala Leu Lys Leu Leu Lys Glu Trp
195 200 205
Gly Ser Leu Glu Asn Ile Gln Lys Asn Leu Asp Gln Val Lys Pro Glu
210 215 220
Arg Val Arg Glu Ala Ile Arg Asn Asn Leu Asp Lys Leu Gln Met Ser
225 230 235 240
Leu Glu Leu Ser Arg Leu Arg Thr Asp Leu Pro Leu Glu Val Asp Phe
245 250 255
Arg Arg Arg Arg Glu Pro Asp Arg Glu Gly Leu Arg Ala Phe Leu Glu
260 265 270
Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu Glu Ser
275 280 285
Pro Lys Ala Leu Glu Glu Ala Leu Trp Pro Pro Pro Glu Gly Ala Phe
290 295 300
Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp Leu Leu
305 310 315 320
Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro Glu Pro
325 330 335
Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu Ala Lys
340 345 350
Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro Pro Gly
355 360 365
Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn Thr Thr
370 375 380
Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu Glu Ala
385 390 395 400
Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu Trp Ser
405 410 415
Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu Val Glu
420 425 430
Arg Pro Leu Ser Val Val Leu Ala His Met Glu Ala Thr Gly Val Arg
435 440 445
Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala Glu Glu
450 455 460
Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His Pro Phe
465 470 475 480
Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp Glu Leu
485 490 495
Gly Leu Pro Pro Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg Ser Thr
500 505 510
Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile Val Glu
515 520 525
Lys Ile Leu Gln Tyr Arg Glu Leu Ala Lys Leu Lys Ser Thr Tyr Ile
530 535 540
Asp Pro Leu Pro Arg Leu Val His Pro Lys Thr Gly Arg Leu His Thr
545 550 555 560
Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp
565 570 575
Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln Arg Ile
580 585 590
Arg Lys Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala Leu Asp
595 600 605
Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly Asp Glu
610 615 620
Asn Leu Ile Arg Val Phe Arg Glu Gly Lys Asp Ile His Thr Glu Thr
625 630 635 640
Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro Leu Met
645 650 655
Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly Met Ser
660 665 670
Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu Ala Gln
675 680 685
Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg Ala Trp
690 695 700
Ile Glu Lys Thr Leu Glu Glu Gly Arg Gln Arg Gly Tyr Val Glu Thr
705 710 715 720
Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn Ala Arg Val Lys
725 730 735
Arg Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro Val Gln
740 745 750
Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Arg Leu Phe Pro
755 760 765
Arg Leu Pro Glu Val Gly Ala Arg Met Leu Leu Gln Val His Asp Glu
770 775 780
Leu Leu Leu Glu Ala Pro Lys Glu Arg Ala Glu Glu Ala Ala Ala Leu
785 790 795 800
Ala Arg Glu Val Met Glu Gly Val Trp Pro Leu Ala Val Pro Leu Glu
805 810 815
Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Gly
820 825 830
<210> 4
<211> 830
<212> PRT
<213> 人工序列
<220>
<223> 人工序列说明:合成多肽
<400> 4
Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu Val Asp Gly
1 5 10 15
His His Leu Ala Tyr Arg Asn Phe Phe Thr Leu Lys Gly Pro Thr Thr
20 25 30
Ser Arg Gly Glu Pro Val Gln Gly Val Tyr Gly Phe Ala Lys Ser Leu
35 40 45
Ala Lys Ala Leu Lys Glu Asp Gly Asp Val Val Ile Val Val Phe Asp
50 55 60
Ala Lys Ala Pro Ser Phe Arg His Glu Thr Tyr Gly Ala Tyr Lys Ala
65 70 75 80
Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu Ala Leu Met
85 90 95
Lys Glu Leu Val Asp Leu Leu Gly Leu Glu Arg Leu Glu Val Pro Gly
100 105 110
Phe Glu Ala Asp Asp Val Leu Ala Ala Leu Ala Lys Ile Ala Glu Arg
115 120 125
Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Arg Asp Leu Phe Gln
130 135 140
Leu Leu Ser Asp Arg Ile Ala Val Leu His Pro Glu Gly His Leu Ile
145 150 155 160
Thr Pro Gly Trp Leu Trp Glu Arg Tyr Gly Leu Arg Pro Glu Gln Trp
165 170 175
Val Asp Phe Arg Ala Leu Ala Gly Asp Pro Ser Asp Asn Ile Pro Gly
180 185 190
Val Lys Gly Ile Gly Glu Lys Thr Ala Leu Lys Leu Leu Lys Glu Trp
195 200 205
Gly Ser Leu Glu Asn Ile Gln Lys Asn Leu Asp Gln Val Lys Pro Glu
210 215 220
Arg Val Arg Glu Ala Ile Arg Asn Asn Leu Asp Lys Leu Gln Met Ser
225 230 235 240
Leu Glu Leu Ser Arg Leu Arg Thr Asp Leu Pro Leu Glu Val Asp Phe
245 250 255
Arg Arg Arg Arg Glu Pro Asp Arg Glu Gly Leu Arg Ala Phe Leu Glu
260 265 270
Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu Glu Ser
275 280 285
Pro Lys Ala Leu Glu Glu Ala Leu Trp Pro Pro Pro Glu Gly Ala Phe
290 295 300
Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp Leu Leu
305 310 315 320
Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro Glu Pro
325 330 335
Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu Ala Lys
340 345 350
Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro Pro Gly
355 360 365
Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn Thr Thr
370 375 380
Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu Glu Ala
385 390 395 400
Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu Trp Gly
405 410 415
Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu Val Glu
420 425 430
Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly Val Arg
435 440 445
Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala Glu Glu
450 455 460
Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His Pro Phe
465 470 475 480
Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp Glu Leu
485 490 495
Gly Leu Pro Pro Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg Ser Thr
500 505 510
Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile Val Glu
515 520 525
Lys Ile Leu Gln Tyr Arg Glu Leu Ala Lys Leu Lys Ser Thr Tyr Ile
530 535 540
Asp Pro Leu Pro Arg Leu Val His Pro Lys Thr Gly Arg Leu His Thr
545 550 555 560
Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp
565 570 575
Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln Arg Ile
580 585 590
Arg Lys Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala Leu Asp
595 600 605
Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly Asp Glu
610 615 620
Asn Leu Ile Arg Val Phe Arg Glu Gly Lys Asp Ile His Thr Glu Thr
625 630 635 640
Ala Ala Trp Met Phe Gly Val Pro Pro Glu Gly Val Asp Gly Ala Met
645 650 655
Arg Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu Tyr Gly Met Ser
660 665 670
Ala His Arg Leu Ser Gln Glu Leu Ser Ile Pro Tyr Glu Glu Ala Ala
675 680 685
Ala Phe Ile Glu Arg Tyr Phe Gln Arg Phe Pro Gln Val Arg Ala Trp
690 695 700
Ile Ala His Thr Leu Glu Glu Gly Arg Lys Lys Gly Tyr Val Glu Thr
705 710 715 720
Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn Ala Arg Val Lys
725 730 735
Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Ala Val Gln
740 745 750
Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu Phe Pro
755 760 765
Arg Leu Pro Glu Val Gly Ala Arg Met Leu Leu Gln Val His Asp Glu
770 775 780
Leu Leu Leu Glu Ala Pro Lys Glu Arg Ala Glu Glu Ala Ala Ala Leu
785 790 795 800
Ala Lys Glu Val Met Glu Gly Val Trp Pro Leu Ala Val Pro Leu Glu
805 810 815
Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Gly
820 825 830
<210> 5
<211> 830
<212> PRT
<213> 人工序列
<220>
<223> 人工序列说明:合成多肽
<400> 5
Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu Val Asp Gly
1 5 10 15
His His Leu Ala Tyr Arg Asn Phe Phe Thr Leu Lys Gly Leu Thr Thr
20 25 30
Ser Arg Gly Glu Pro Val Gln Gly Val Tyr Gly Phe Ala Lys Ser Leu
35 40 45
Ala Lys Ala Leu Lys Glu Asp Gly Asp Val Val Ile Val Val Phe Asp
50 55 60
Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Ala Tyr Lys Ala
65 70 75 80
Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu Ala Leu Met
85 90 95
Lys Glu Leu Val Asp Leu Leu Gly Leu Glu Arg Leu Glu Val Pro Gly
100 105 110
Phe Glu Ala Asp Asp Val Leu Ala Ala Leu Ala Lys Ile Ala Glu Arg
115 120 125
Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Arg Asp Leu Phe Gln
130 135 140
Leu Leu Ser Asp Arg Ile Ala Val Leu His Pro Glu Gly His Leu Ile
145 150 155 160
Thr Pro Gly Trp Leu Trp Glu Arg Tyr Gly Leu Arg Pro Glu Gln Trp
165 170 175
Val Asn Phe Arg Ala Leu Ala Gly Asp Pro Ser Asp Asn Ile Pro Gly
180 185 190
Val Lys Gly Ile Gly Glu Lys Thr Ala Leu Lys Leu Leu Lys Glu Trp
195 200 205
Gly Ser Leu Glu Asn Ile Gln Lys Asn Leu Asp Gln Val Lys Pro Glu
210 215 220
Arg Val Arg Glu Ala Ile Arg Asn Asn Leu Asp Lys Leu Gln Met Ser
225 230 235 240
Leu Glu Leu Ser Cys Leu Arg Thr Asp Leu Pro Leu Glu Val Asp Phe
245 250 255
Arg Arg Arg Arg Glu Pro Asp Arg Glu Gly Leu Arg Ala Phe Leu Glu
260 265 270
Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu Glu Ser
275 280 285
Pro Lys Ala Leu Glu Glu Ala Leu Trp Pro Pro Pro Glu Gly Ala Phe
290 295 300
Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp Leu Leu
305 310 315 320
Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro Glu Pro
325 330 335
Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu Ala Lys
340 345 350
Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro Pro Gly
355 360 365
Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn Thr Thr
370 375 380
Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu Glu Ala
385 390 395 400
Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu Trp Gly
405 410 415
Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu Val Glu
420 425 430
Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly Val Arg
435 440 445
Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala Glu Glu
450 455 460
Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His Pro Phe
465 470 475 480
Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp Glu Leu
485 490 495
Gly Leu Pro Pro Ile Gly Arg Thr Glu Lys Thr Gly Lys Arg Ser Thr
500 505 510
Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile Val Glu
515 520 525
Lys Ile Leu Gln Tyr Arg Glu Leu Ala Lys Leu Lys Ser Thr Tyr Ile
530 535 540
Asp Pro Leu Pro Arg Leu Val His Pro Lys Thr Gly Arg Leu His Thr
545 550 555 560
Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp
565 570 575
Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln Arg Ile
580 585 590
Arg Lys Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala Leu Asp
595 600 605
Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly Asp Glu
610 615 620
Asn Leu Ile Arg Val Phe Arg Glu Gly Lys Asp Ile His Thr Glu Thr
625 630 635 640
Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro Leu Met
645 650 655
Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly Met Ser
660 665 670
Ala His Arg Leu Ser Gln Glu Leu Ser Ile Pro Tyr Glu Glu Ala Val
675 680 685
Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Gln Val Arg Ala Trp
690 695 700
Ile Ala His Thr Leu Glu Glu Gly Arg Lys Lys Gly Tyr Val Glu Thr
705 710 715 720
Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn Ala Arg Val Lys
725 730 735
Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Ala Val Gln
740 745 750
Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu Phe Pro
755 760 765
Arg Leu Pro Glu Val Gly Ala Arg Met Leu Leu Gln Val His Asp Glu
770 775 780
Leu Leu Leu Glu Ala Pro Lys Glu Arg Ala Glu Glu Ala Ala Ala Leu
785 790 795 800
Ala Lys Glu Val Met Glu Gly Val Trp Pro Leu Ala Val Pro Leu Glu
805 810 815
Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu
820 825 830
<210> 6
<211> 829
<212> PRT
<213> 人工序列
<220>
<223> 人工序列说明:合成多肽
<400> 6
Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu Val Asp Gly
1 5 10 15
His His Leu Ala His Arg Asn Phe Phe Ala Leu Lys Gly Leu Thr Thr
20 25 30
Ser Arg Gly Glu Pro Val Gln Gly Val Tyr Gly Phe Ala Lys Ser Leu
35 40 45
Leu Lys Ala Leu Lys Glu Asp Gly Asp Val Val Ile Val Val Phe Asp
50 55 60
Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Ala Tyr Lys Ala
65 70 75 80
Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu Ala Leu Ile
85 90 95
Lys Glu Leu Val Asp Leu Leu Gly Leu Val Arg Leu Glu Val Pro Gly
100 105 110
Phe Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys Lys Ala Glu Lys
115 120 125
Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp Leu Tyr Gln
130 135 140
Ile Leu Ser Asp Arg Val His Val Leu His Pro Glu Gly Tyr Leu Ile
145 150 155 160
Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro Asp Gln Trp
165 170 175
Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn Leu Pro Gly
180 185 190
Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu Glu Glu Trp
195 200 205
Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu Lys Pro Ala
210 215 220
Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys Leu Ser Trp
225 230 235 240
Asp Pro Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val Asp Phe Ala
245 250 255
Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe Leu Glu Arg
260 265 270
Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu Glu Ser Pro
275 280 285
Lys Ala Leu Glu Glu Ala Leu Trp Pro Pro Pro Glu Gly Ala Phe Val
290 295 300
Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp Leu Leu Ala
305 310 315 320
Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro Glu Pro Tyr
325 330 335
Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu Ala Lys Asp
340 345 350
Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro Pro Gly Asp
355 360 365
Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn Thr Thr Pro
370 375 380
Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu Glu Ala Gly
385 390 395 400
Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asp Leu Trp Gly Arg
405 410 415
Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu Val Glu Arg
420 425 430
Pro Leu Ser Ala Val Leu Ala Arg Met Glu Ala Thr Gly Val Arg Leu
435 440 445
Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala Glu Glu Ile
450 455 460
Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His Pro Phe Asn
465 470 475 480
Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp Glu Leu Gly
485 490 495
Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg Ser Thr Ser
500 505 510
Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile Val Glu Lys
515 520 525
Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr Tyr Ile Asp
530 535 540
Pro Leu Pro Arg Leu Val His Pro Lys Thr Gly Arg Leu His Thr Arg
545 550 555 560
Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp Pro
565 570 575
Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln Arg Ile Arg
580 585 590
Lys Ala Phe Ile Ala Glu Glu Gly His Leu Leu Val Ala Leu Asp Tyr
595 600 605
Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly Asp Glu Asn
610 615 620
Leu Ile Arg Val Phe Gln Glu Gly Lys Asp Ile His Thr Glu Thr Ala
625 630 635 640
Ala Trp Met Phe Gly Val Pro Pro Glu Gly Val Asp Gly Ala Met Arg
645 650 655
Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu Tyr Gly Met Ser Ala
660 665 670
His Arg Leu Ser Gln Glu Leu Ser Ile Pro Tyr Glu Glu Ala Ala Ala
675 680 685
Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Gln Val Arg Ala Trp Ile
690 695 700
Ala His Thr Leu Glu Glu Gly Arg Lys Lys Gly Tyr Val Glu Thr Leu
705 710 715 720
Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn Ala Arg Val Lys Ser
725 730 735
Val Arg Lys Ala Ala Glu Arg Met Ala Phe Asn Met Ala Val Gln Gly
740 745 750
Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu Phe Pro Arg
755 760 765
Leu Pro Glu Val Gly Ala Arg Met Leu Leu Gln Val His Asp Glu Leu
770 775 780
Leu Leu Glu Ala Pro Lys Glu Arg Ala Glu Glu Ala Ala Ala Leu Ala
785 790 795 800
Lys Glu Val Met Glu Gly Val Trp Pro Leu Ala Val Pro Leu Glu Val
805 810 815
Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Gly
820 825
<210> 7
<211> 829
<212> PRT
<213> 人工序列
<220>
<223> 人工序列说明:合成多肽
<400> 7
Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu Val Asp Gly
1 5 10 15
His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly Leu Thr Thr
20 25 30
Ser Arg Gly Glu Pro Val Gln Gly Val Tyr Gly Phe Ala Lys Ser Leu
35 40 45
Leu Lys Ala Leu Lys Glu Asp Gly Glu Val Ala Ile Val Val Phe Asp
50 55 60
Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu Ala Tyr Lys Ala
65 70 75 80
Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu Ala Leu Ile
85 90 95
Lys Glu Leu Val Asp Leu Leu Gly Leu Val Arg Leu Glu Val Pro Gly
100 105 110
Phe Glu Ala Asp Asp Val Leu Ala Ala Leu Ala Lys Lys Ala Glu Arg
115 120 125
Glu Gly Tyr Glu Val Arg Ile Leu Ser Ala Asp Arg Asp Leu Tyr Gln
130 135 140
Leu Leu Ser Asp Arg Ile His Leu Leu His Pro Glu Gly Tyr Leu Ile
145 150 155 160
Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro Asp Gln Trp
165 170 175
Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn Leu Pro Gly
180 185 190
Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu Glu Glu Trp
195 200 205
Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu Lys Pro Ala
210 215 220
Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys Leu Ser Trp
225 230 235 240
Asp Pro Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val Asp Phe Ala
245 250 255
Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe Leu Glu Arg
260 265 270
Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu Glu Ser Pro
275 280 285
Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly Ala Phe Val
290 295 300
Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp Leu Leu Ala
305 310 315 320
Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro Glu Pro Tyr
325 330 335
Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu Ala Lys Asp
340 345 350
Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro Pro Gly Asp
355 360 365
Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn Thr Thr Pro
370 375 380
Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu Glu Ala Gly
385 390 395 400
Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu Trp Gly Arg
405 410 415
Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu Val Glu Arg
420 425 430
Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly Val Arg Leu
435 440 445
Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala Glu Glu Ile
450 455 460
Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His Pro Phe Asn
465 470 475 480
Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp Glu Leu Gly
485 490 495
Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg Ser Thr Ser
500 505 510
Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile Val Glu Lys
515 520 525
Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr Tyr Ile Asp
530 535 540
Pro Leu Pro Arg Leu Val His Pro Lys Thr Gly Arg Leu His Thr Arg
545 550 555 560
Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp Pro
565 570 575
Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln Arg Ile Arg
580 585 590
Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala Leu Asp Tyr
595 600 605
Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly Asp Glu Asn
610 615 620
Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr Glu Thr Ala
625 630 635 640
Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro Leu Met Arg
645 650 655
Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly Met Ser Ala
660 665 670
His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu Ala Gln Ala
675 680 685
Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg Ala Trp Ile
690 695 700
Glu Arg Thr Leu Glu Glu Gly Arg Gln Arg Gly Tyr Val Glu Thr Leu
705 710 715 720
Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn Ala Arg Val Lys Arg
725 730 735
Val Arg Lys Ala Ala Glu Arg Met Ala Phe Asn Met Pro Val Gln Gly
740 745 750
Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Arg Leu Phe Pro Arg
755 760 765
Leu Pro Glu Val Gly Ala Arg Met Leu Leu Gln Val His Asp Glu Leu
770 775 780
Leu Leu Glu Ala Pro Lys Glu Arg Ala Glu Glu Ala Ala Gln Leu Ala
785 790 795 800
Lys Glu Thr Met Glu Gly Val Trp Pro Leu Ala Val Pro Leu Glu Val
805 810 815
Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu
820 825
<210> 8
<211> 832
<212> PRT
<213> 水生栖热菌(Thermus aquaticus)
<400> 8
Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15
Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly
20 25 30
Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala
35 40 45
Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val
50 55 60
Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly
65 70 75 80
Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu
85 90 95
Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu
100 105 110
Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys
115 120 125
Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp
130 135 140
Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly
145 150 155 160
Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro
165 170 175
Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn
180 185 190
Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu
195 200 205
Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu
210 215 220
Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys
225 230 235 240
Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val
245 250 255
Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe
260 265 270
Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu
275 280 285
Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly
290 295 300
Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp
305 310 315 320
Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro
325 330 335
Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu
340 345 350
Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro
355 360 365
Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn
370 375 380
Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu
385 390 395 400
Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu
405 410 415
Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu
420 425 430
Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly
435 440 445
Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala
450 455 460
Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His
465 470 475 480
Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp
485 490 495
Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg
500 505 510
Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile
515 520 525
Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr
530 535 540
Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg Leu
545 550 555 560
His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser
565 570 575
Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln
580 585 590
Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala
595 600 605
Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly
610 615 620
Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr
625 630 635 640
Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro
645 650 655
Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly
660 665 670
Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu
675 680 685
Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg
690 695 700
Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val
705 710 715 720
Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg
725 730 735
Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro
740 745 750
Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu
755 760 765
Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His
770 775 780
Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala
785 790 795 800
Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro
805 810 815
Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu
820 825 830
<210> 9
<211> 2493
<212> DNA
<213> 人工序列
<220>
<223> 人工序列说明:合成多核苷酸
<400> 9
atgctgccgc tgtttgagcc gaaaggtcgt gtgctgctgg ttgacggtca tcatctggcg 60
tatcgtaact tctttacgct gaaaggtccg accaccagcc gtggtgagcc ggtgcaaggt 120
gtttacggct tcgcgaaaag cctggcgaag gcgctgaaag aagacggcga tgtggttatc 180
gtggttttcg acgcgaaagc gccgagcttt cgtcacgagg cgtacggtgc gtataaagcg 240
ggtcgtgcgc cgaccccgga ggacttcccg cgtcagctgg cgctgatgaa ggaactggtg 300
gatctgctgg gtctggagcg tctggaagtt ccgggctttg aagcggatga tgttctggcg 360
gcgctggcga agatagcgga gcgtgagggt tacgaagtgc gtattctgac cgcggaccgt 420
gacctgttcc aactgctgag cgaccgtatc gcgcttctgc acccggaagg tcacctgatt 480
accccgggct ggctgtggga gcgttatggt ctgcgtccgg aacagtgggt ggattttcgt 540
gcgctggcgg gtgacccgag cgataacatc ccgggcgtta aaggtattag cgagaagatc 600
gcgctgaagc tgctgaaaga gtggggcagc ctggaaaaca tccagaaaaa cctggctcag 660
gtgaagccgg aacgtgttcg tgaggcgatt cgtaacaacc tggacaagct gcaaatgagc 720
ctggaactga gccgtctgcg taccgacctg ccgctggaag ttgatttccg tcgtcgtcgt 780
gaaccggatc gtgagggtct gggtgcgttc ctggaacgtc tggagtttgg tagcctgctg 840
cacgaatttg gcctcttaga atcacccaaa gccctggaag aagcactgtg gcctccacct 900
gaaggcgcct ttgttggttt tgttttgtct cgtaaagaac ctatgtgggc cgatttactg 960
gccttagccg ctgcacgtgg tggtcgtgtc catcgcgcac cagaacctta taaagcactg 1020
cgtgatctta aagaagctcg tggtctcctc gccaaagact tatccgtatt agcactccgc 1080
gagggtttag ggctgccacc tggtgatgat ccaatgttac ttgcatatct cctggatccc 1140
tctaatacaa ccccggaagg cgtggctcgt cgttatggtg atgaatggac tgaagaagct 1200
ggtgaacgtg cggctttgtc tgaacgctta ttcgctgacc tgtggggccg tctggaagga 1260
gaggaacgct tactctggtt atatcgtgaa gttgaacgcc cactgtcagc agtacttgcg 1320
cacatggaag ctaccggggt ccgcttagat gttgcctatc tccgtgctct gagtcttgaa 1380
gtagccgaag agattgcgcg cctagaagcc gaagtatttc gtctggccgg tcacccgttc 1440
aaccttaatt cccgtgatca actggaacgc gttttgtttg atgaacttgg cctgcccgca 1500
attggtaaaa ctgaaaaaac tggtaaacgt tcgacctccg ccgcagtcct tgaagccctg 1560
cgtgaagccc acccaattgt cgaaaaaatc ctgcagtacc gcgaactcac taaacttaaa 1620
tctacctata ttgacccgct gccgcgtctg gtgcacccga aaaccggacg tcttcacacc 1680
cgttttaatc aaactgctac cgcgactgga cgtttaagct catccgatcc caacttgcaa 1740
aatattcctg tccgtacccc actagggcaa cgtattcgcc gcgcatttat cgcagaggaa 1800
ggttggttgc tggtggcatt agattatagc caaattgaat tacgtgttct tgcgcattta 1860
tccggtgacg aaaatctcat tcgtgttttt caggagggac gtgatattca cacagaaacc 1920
gcttcatgga tgtttggtgt tccgcgtgaa gccgtcgacc cgttaatgcg tcgcgctgca 1980
aaaaccatta atttcggtgt tctgtatggt atgagtgcac atcggttatc acaagaactc 2040
gctatcccgt acgaagaagc tcaagcattt attgaacgtt attttcagag ttttcctaag 2100
gttcgtgcgt ggatcgcgca caccctggaa gagggtcgta agaaaggcta cgtggagacc 2160
ctgttcggtc gtcgtcgtta cgttccggac ctgaacgcgc gtgtgaaaag cgttcgtgaa 2220
gcggcggagc gtatggcgtt caacatggcg gtgcaaggta ccgcggcgga cctgatgaag 2280
ctggcgatgg tgaagctgtt tccgcgtctg ccggaagtgg gtgcgcgtat gctgctgcag 2340
gtgcacgatg aactgctgct ggaggcgccg aaagagcgtg cggaagaggc ggcggcgctg 2400
gcgaaggaag tgatggaggg tgtttggccg ctggcggtgc cgctggaagt ggaagttggt 2460
atcggtgaag actggctgag cgcgaagggc taa 2493
<210> 10
<211> 2545
<212> DNA
<213> 人工序列
<220>
<223> 人工序列说明:合成多核苷酸
<400> 10
atgctgccgc tgtttgagcc gaaaggtcgt gtgctgctgg ttgacggtca tcatctggcg 60
tatcgtaact tctttacgct gaaaggtctg accaccagcc gtggtgagcc ggtgcaaggt 120
gtttacggct tcgcgaaaag cctggcgaag gcgctgaaag aagacggcga tgtggttatc 180
gtggttttcg acgcggaagc gccgagcttt cgtcacgagg cgtacggtgc gtataaagcg 240
ggtcgtgcgc cgacccggga ggacttcccg cgtcagctgg cgctgatgaa ggaactggtg 300
gatctgctgg gtctggaacg tctggaagtt ccgggctttg aagcggatga tgttctggcg 360
gcgctggcga agatagcgga acgtgagggt tacgaagtgc gtattctgac cgcggaccgt 420
gacctgttcc aactgctgag cgaccgtatc gcggttctgc acccggaagg tcacctgatt 480
accccgggct ggctgtggga gcgttatggt ctgcgtccgg aacagtgggt ggattttcgt 540
gcgctggcgg gtgaccctag cgataacatc ccgggcgtta aaggtattag cgagaagacc 600
gcgctgaagc tgctgaaaga gtggggcagc ctggaaaaca tccagaaaaa cctggctcag 660
gtgaagccgg aacgtgttcg tgaggcgatt cgtaacaacc tggacaagct gcaaatgagc 720
ctggaactga gccgtctgcg taccgacctg ccgctggaag ttgatttccg tcgtcgtcgt 780
aaaccggatc gtgagggtct gcgtgcattc atggaacgtc tggagtttga tagcctgctg 840
cacgaatttg gcctcttaga atcacccaag gccctggaag aagcactgtg gcccccacct 900
gaaggcgcct ttgttggttt tgttttgtct cgtaaagaac ctatgtgggc cgatttactg 960
gccttagccg ctgcacgtgg tggtcgtgtc catcgcgcac cagaacctta taaagcactg 1020
cgtgatctta aagaagctcg tggtctcctc gccaaagact tatccgtatt agcactccgc 1080
gagggtttag ggctgccacc tggtgatgat ccaatgttac ttgcatatct cctggatccc 1140
tctaatacaa ccccggaagg cgtggctcgt cgttatggtg gtgaatggac tgaagaagct 1200
ggtgaacgtg cggctttgtc cgaacgctta ttcgctgacc tgtggggccg tctggaagaa 1260
gaggaacgct tactctggtt atatcatgaa gttgaacgcc cactgtcagc agtacttgcg 1320
cacatggaag ctaccggggt ccgcttagat gttgcctatc tccgtgctct gagtcttgaa 1380
gtagccgaag aaattgcgcg cctggaagcc gaagtatttc gtctggcggg ccacccgttt 1440
aacctgaaca gccgtgacca gctggaacgt gttctgtttg atgaactggg tctgccgccg 1500
atcggcaaga ccgagaaaac cggtaaacgt agcaccagcg cggcggtgct ggaagcgctg 1560
cgtgaggcgc acccgatcgt tgagaagatt ctgcaatacc gtgaactggc gaagctgaaa 1620
agcacctata ttgacccgct gccgcgtctg gtgcacccga aaaccggtcg tctgcacacc 1680
cgtttcaacc aaaccgcgac cgcgaccggc cgtctgagca gcagcgatcc gaacctgcag 1740
aacatcccgg ttcgtacccc gctgggtcaa cgtatccgta aggcgtttat cgcagaagaa 1800
ggttggctgc tggtggcatt agattatagc caaattgaac tgcgtgttct ggcgcacctg 1860
agcggtgacg agaacctgat ccgtgtgttc cgtgaaggca aagatattca caccgagacc 1920
gcttcatgga tgtttggtgt tccgcgtgaa gccgtcgacc cgttaatgcg tcgcgctgca 1980
aaaaccatta attttggtgt tctgtatggt atgagcgcgc accgtctgag ccaggaactg 2040
agcatcccgt atgaagaggc ggcggcgttt attgagcgtt atttccagcg ctttccgcaa 2100
gtgcgtgcgt ggatcgcgca caccctggaa gagggtcgta agaaaggcta cgtggagacc 2160
ctgttcggtc gtcgtcgtta cgttccggac ctgaacgcgc gtgtgaaaag cgttcgtgaa 2220
gcagcggagc gtatggcgtt caacatggcg gtgcaaggta ccgcggcgga cctgatgaag 2280
ctggcgatgg tgaagctgtt tccgcgtctg cgtccgctgg gcgttcgtat gctgctgcag 2340
gttcacgatg aactgctgct ggaggcgccg aaagagcgtg cggaagaggc ggcggcgctg 2400
gcgaaggaag tgatggaggg tgtttggccg ctggcggtgc cgctggaagt ggaagttggt 2460
atcggtgaag actggctgag cgcgaagggc taatatctaa ctaagcttga cctgtgaagt 2520
gaaaaatggc gcacatggcg acatt 2545
<210> 11
<211> 2493
<212> DNA
<213> 人工序列
<220>
<223> 人工序列说明:合成多核苷酸
<400> 11
atgctgccgc tgtttgagcc gaaaggtcgt gtgctgctgg ttgacggtca tcatctggcg 60
tatcgtaact tctttacgct gagaggtctg accaccagcc gtggtgagcc tgtgcaaggt 120
gtttacggct tcgcgaaaag cctggcgaag gcgctgaaag aagacggcga tgtggttatc 180
gtggttttcg acgcgaaagc gccgagcttt cgtcacgagg cgtacggtgc gtataaagcg 240
ggtcgtgcgc cgaccccgga ggacttcccg cgtcagctgg cgctgatgaa ggaactggtg 300
gatctgctgg gtctggagcg tctggaagtt ccgggccttg aagcggatga tgttttggcg 360
gcgctggcga agatagcgga acgtgagggt tacgaagtgc gtattctgac cgcggaccgt 420
gacctgttcc aactgctgag cgaccgtatc gcggttctgc acccggaagg tcacctgatt 480
accccgggct ggctgtggga gcgttatggt ctgcgtccgg aacagtgggt ggattttcgt 540
gcgctgacgg gtgacccgag cgataacatc ccgggcgtta aaggtattgg cgagaagacc 600
gcgctgaagc tgctgaaaga gtggggcagc ctggaaaaca tccagaaaaa cctggatcag 660
gtgaagccgg aacgtgttcg tgaggcgatt cgtaacaacc tggacaagct gcaaatgagc 720
ctggaactga gccgtctgcg taccgacctg ccgctggaag ttgatttccg tcgtcgtcgt 780
gaaccggatc gtgagggtct gcgtgcgttc ctggaacgtc tggagtttgg tagcctgctg 840
cacgaatttg gcctcttaga atcacccaag gccctggaag aagcactgtg gcctccacct 900
gaaggcgcct ttgttggttt tgttttgtct cgtaaagaac ctatgtgggc cgatttactg 960
gccttagccg ctgcacgtgg tggtcgtgtc catcgcgcac cagaacctta taaagcactg 1020
cgtgacctta aagaagctcg tggtctcctc gccaaagact tatccgtatt agcactccgc 1080
gagggtttag ggctgccacc tggtgatgat ccaatgttac ttgcatatct cctggatccc 1140
tctaatacaa ccccggaagg cgtggctcgt cgttatggtg gtgaatggac tgaagaagct 1200
ggtgaacgtg cggctttgtc tgaacgctta ttcgctaacc tgtggagccg tctggaagga 1260
gaggaacgct tactctggtt atatcgtgaa gttgaacgcc cactgtcagt agtactagcg 1320
cacatggaag ctaccggggt ccgcttagat gttgcctatc tccgtgctct gagtcttgaa 1380
gtagccgaag aaattgcgcg cctggaagcc gaagtatttc gtctggcggg ccacccgttt 1440
aacctgaaca gccgtgacca gctggaacgt gttctgtttg atgaactggg tctgccgccg 1500
atcggcaaga ccgagaaaac cggtaaacgt agcaccagcg cggcggtgct ggaagcgctg 1560
cgtgaggcgc acccgatcgt tgagaagatt ctgcaatacc gtgaactggc gaagctgaaa 1620
agcacctata ttgacccgct gccgcgtctg gtgcacccga aaaccggtcg tctgcacacc 1680
cgtttcaacc aaaccgcgac cgcgaccggc cgtctgagca gcagcgatcc gaacctgcag 1740
aacatcccgg ttcgtacccc gctgggtcaa cgtatccgta aggcgtttat cgcagaagaa 1800
ggttggctgc tggtggcatt agattatagc caaattgaac tgcgtgttct ggcgcacctg 1860
agcggtgacg agaacctgat ccgtgtgttc cgtgaaggca aagatattca caccgagacc 1920
gcttcatgga tgtttggtgt tccgcgtgaa gccgtcgacc cgttaatgcg tcgcgctgca 1980
aaaaccatta attttggtgt tctgtatggt atgagtgcac atcggttatc acaagaactc 2040
gctatcccgt atgaagaagc tcaagcattt attgaacgtt attttcagag ttttcctaag 2100
gttcgtgctt ggattgaaaa aacattggaa gagggtcgtc agcgtggcta cgtggaaacc 2160
ctgtttggtc gtcgtcgtta cgttccggat ctgaacgcgc gtgtgaaaag ggttcgtgaa 2220
gcggcggagc gtatggcgtt caacatgccg gttcaaggta ccgcggcgga cctgatgaag 2280
ctggcgatgg ttcgtctgtt cccgcgtctg ccggaagtgg gtgcgcgtat gctgctgcag 2340
gttcacgatg aactgctgct ggaggcgccg aaagagcgtg cggaagaggc ggcggcgctg 2400
gcgagggaag tgatggaggg tgtttggccg ctggcggtgc cgctggaagt ggaagttggt 2460
attggtgaag actggctgag cgcgaagggc taa 2493
<210> 12
<211> 2493
<212> DNA
<213> 人工序列
<220>
<223> 人工序列说明:合成多核苷酸
<400> 12
atgctgccgc tgtttgagcc gaaaggtcgt gtgctgctgg ttgacggtca tcatctggcg 60
tatcgtaact tctttacgct gaaaggtccg accaccagcc gtggtgagcc ggtgcaaggt 120
gtttacggct tcgcgaaaag cctggcgaag gcgctgaaag aagacggcga tgtggttatc 180
gtggttttcg acgcgaaagc gccgagcttt cgtcacgaga cgtacggtgc gtataaagcg 240
ggtcgtgcgc cgaccccgga ggacttcccg cgtcagctgg cgctgatgaa ggaactggtg 300
gatctgctgg gtctggagcg tctggaagtt ccgggctttg aagcggatga tgttctggcg 360
gcgctggcga agatagcgga gcgtgagggt tacgaagtgc gtattctgac cgcggaccgt 420
gacctgttcc aactgctgag cgaccgtatc gcggttctgc acccggaagg tcacctgatt 480
accccgggct ggctgtggga gcgttatggt ctgcgtccgg aacagtgggt ggattttcgt 540
gcgctggcgg gtgacccgag cgataacatc ccgggcgtta aaggtattgg cgagaagacc 600
gcgctgaagc tgctgaaaga gtggggcagc ctggaaaaca tccagaaaaa cctggatcag 660
gtgaagccgg aacgtgttcg tgaggcgatt cgtaacaacc tggacaagct gcaaatgagt 720
ctggaactga gccgtctgcg taccgacctg ccgctggaag ttgatttccg tcgtcgtcgt 780
gaaccggatc gtgagggtct gcgtgcgttc ctggaacgtc tggagtttgg tagcctgctg 840
cacgaatttg gcctcttaga atcacccaag gccctggaag aagcactgtg gcctccacct 900
gaaggcgcct ttgttggttt tgttttgtct cgtaaagaac ctatgtgggc cgatttactg 960
gccttagccg ctgcacgtgg tggtcgtgtc catcgcgcac cagaacctta taaagcactg 1020
cgtgacctta aagaagctcg tggtctcctc gccaaagact tatccgtatt agcactccgc 1080
gagggtttag ggctgccacc tggtgatgat ccaatgttac ttgcatatct cctggatccc 1140
tctaatacaa ccccggaagg cgtggctcgt cgttatggtg gtgaatggac tgaagaagct 1200
ggtgaacgtg cggctttgtc tgaacgctta ttcgctaacc tgtggggccg tctggaagga 1260
gaggaacgct tactctggtt atatcgtgaa gttgaacgcc cactgtcagc agtacttgcg 1320
cacatggaag ctaccggggt ccgcttagat gttgcctatc tccgtgctct gagtcttgaa 1380
gtagccgaag aaattgcgcg cctggaagcc gaagtatttc gtctggcggg ccacccgttt 1440
aacctgaaca gccgtgacca gctggaacgt gttctgtttg atgaactggg tctgccgccg 1500
atcggcaaga ccgagaaaac cggtaaacgt agcaccagcg cggcggtgct ggaagcgctg 1560
cgtgaggcgc acccgatcgt tgagaagatt ctgcaatacc gtgaactggc gaagctgaaa 1620
agcacctata ttgacccgct gccgcgtctg gtgcacccga aaaccggtcg tctgcacacc 1680
cgtttcaacc aaaccgcgac cgcgaccggc cgtctgagca gcagcgatcc gaacctgcag 1740
aacatcccgg ttcgtacccc gctgggtcaa cgtatccgta aggcgtttat cgcagaagaa 1800
ggttggctgc tggtggcatt agattatagc caaattgaac tgcgtgttct ggcgcacctg 1860
agcggtgacg agaacctgat ccgtgtgttc cgtgaaggca aagatattca caccgagacc 1920
gcggcgtgga tgtttggtgt gccgccggaa ggtgttgatg gtgcgatgcg tcgtgcggcg 1980
aagaccgtga acttcggtgt tctgtatggc atgagcgcgc accgtctgag ccaggaactg 2040
agcatcccgt acgaagaggc ggcggcgttt attgagcgtt atttccagcg ctttccgcaa 2100
gtgcgtgcgt ggatcgcgca caccctggaa gagggtcgta agaaaggcta cgtggagacc 2160
ctgttcggtc gtcgtcgtta cgttccggac ctgaacgcgc gtgtgaaaag cgttcgtgaa 2220
gcagcggagc gtatggcgtt caacatggcg gtgcaaggta ccgcggcgga cctgatgaag 2280
ctggcgatgg tgaagctgtt tccgcgtctg ccggaagtgg gtgcgcgtat gctgctgcag 2340
gtgcacgatg aactgctgct ggaggcgccg aaagagcgtg cggaagaggc ggcggcgctg 2400
gcgaaggaag tgatggaggg tgtttggccg ctggcggtgc cgctggaagt ggaagttggt 2460
atcggtgaag actggctgag cgcgaagggc taa 2493
<210> 13
<211> 2493
<212> DNA
<213> 人工序列
<220>
<223> 人工序列说明:合成多核苷酸
<400> 13
atgctgccgc tgtttgagcc gaaaggtcgt gtgctgctgg ttgacggtca tcatctggcg 60
tatcgtaact tctttacgct gaaaggtctg accaccagcc gtggtgagcc tgtgcaaggt 120
gtttacggct tcgcgaaaag cctggcgaag gcgctgaaag aagacggcga tgtggttatc 180
gtggttttcg acgcgaaagc gccgagcttt cgtcacgagg cgtacggtgc gtataaagcg 240
ggtcgtgcgc cgaccccgga ggacttcccg cgtcagctgg cgctgatgaa ggaactggtg 300
gatctcctgg gtctggagcg tctggaagtt ccgggctttg aagcggatga tgttctggcg 360
gcgctggcga agatagcgga acgtgagggt tacgaagtgc gtattctgac cgcggaccgt 420
gacctgttcc aactgctgag cgaccgtatc gcggttctgc acccggaagg tcacctaatt 480
accccgggct ggctgtggga gcgttatggt ctgcgtccgg aacagtgggt gaattttcgt 540
gcgctggcgg gtgacccgag cgataacatc ccgggcgtta aaggtattgg cgagaagacc 600
acgctgaagc tgctgaaaga gtggggcagc ctggaaaaca tccagaaaaa cctggatcag 660
gtgaagccgg aacgtgttcg tgaggcgatt cgtaacaacc tggacaagct gcaaatgagc 720
ctggaactga gctgtctgcg taccgacctg ccgctggaag ttgatttccg tcgtcgtcgt 780
gaaccggatc gtgagggtct gcgtgcgttc ctggaacgtc tggagtttgg tagcctgctg 840
cacgaatttg gcctcttaga gtcacccaag gccctggaag aagcactgtg gcctccacct 900
gaaggcgcct ttgttggttt tgttttgtct cgtaaagaac ctatgtgggc cgatttactg 960
gccttagccg ctgcacgtgg tggtcgtgtc catcgcgcac cagaacctta taaagcactg 1020
cgtgatctta aagaagctcg tggtctcctc gccaaagact tatccgtatt agcactccgc 1080
gagggtttag ggctgccacc tggtgatgat ccaatgttac ttgcatatct cctggatccc 1140
tctaatacaa ccccggaagg cgtggctcgt cgttatggtg gtgaatggac tgaagaagct 1200
ggtgaacgtg cggctttgtc tgaacgctta ttcgctaacc tgtggggccg tctggaagga 1260
gaggaacgct tactctggtt atatcgtgaa gttgaacgcc cactgtcagc agtacttgcg 1320
cacatggaag ctaccggggt ccgcttagat gttgcctatc tccgtgctct gagtcttgaa 1380
gtagccgaag aaattgcgcg cctggaagcc gaagtatttc gtctggcggg ccacccgttt 1440
aacctgaaca gccgtgacca gctggaacgt gttctgtttg atgaactggg tctgccgccg 1500
atcggcagga ccgagaaaac cggtaaacgt agcaccagcg cggcggtgct ggaagcgctg 1560
cgtgaggcgc acccgatcgt tgagaagatt ctgcaatacc gtgaactggc gaagctgaaa 1620
agcacctata ttgacccgct gccgcgtctg gtgcacccga aaaccggtcg tctgcacacc 1680
cgtttcaacc aaaccgcgac cgcgaccggc cgtctgagca gcagcgatcc gaacctgcag 1740
aacatcccgg ttcgtacccc gctgggtcaa cgtatccgta aggcgtttat cgcagaagaa 1800
ggttggctgc tggtggcatt agattatagc caaattgaac tgcgtgttct ggcgcacctg 1860
agcggtgacg agaacctgat ccgtgtgttc cgtgaaggca aagatattca caccgagacc 1920
gcttcatgga tgtttggtgt tccgcgtgaa gccgtcgacc cgttaatgcg tcgcgctgca 1980
aaaaccatta attttggtgt tctgtatggt atgagcgcgc accgtctgag ccaggaactg 2040
agcatcccgt atgaagaggc ggtggcgttt attgagcgtt atttccagag ctttccgcaa 2100
gtgcgtgcgt ggatcgcgca caccctggaa gagggtcgta agaaaggcta cgtggagacc 2160
ctgttcggtc gtcgtcgtta cgttccggac ctgaacgcgc gtgtgaaaag cgttcgtgaa 2220
gcggcggagc gtatggcgtt caacatggcg gtgcaaggta ccgcggcgga cctgatgaag 2280
ctggcgatgg tgaagctgtt tccgcgtctg ccggaagtgg gtgcgcgtat gctgctgcag 2340
gtgcacgatg aactgctgct ggaggcgccg aaagagcgtg cggaagaggc ggcggcgctg 2400
gcgaaggaag tgatggaggg tgtttggccg ctggcggtgc cgctggaagt cgaagtgggc 2460
atcggtgaag actggctgtc ggcaaaagaa taa 2493
<210> 14
<211> 2502
<212> DNA
<213> 人工序列
<220>
<223> 人工序列说明:合成多核苷酸
<400> 14
tatgctgccg ctgtttgagc cgaaaggtcg tgtgctgctg gttgacggtc atcatctggc 60
gcatcgtaac ttcttcgcgc tgaaaggtct gaccaccagc cgtggtgagc cggtgcaagg 120
tgtttacggc ttcgcgaaaa gcctgctgaa ggcgctgaaa gaagacggcg atgtggttat 180
cgtggttttc gacgcgaaag cgccgagctt tcgtcacgag gcgtacggtg cgtataaagc 240
aggtcgtgcg ccgaccccgg aagacttccc gcgtcaactg gcgctgatta aggagctggt 300
tgatctgctg ggtctggtgc gtctggaagt gccgggcttt gaagcggatg atgtgctggc 360
gaccctggcg aagaaagcag aaaaagaagg atatgaagta cgcatcctga cagccgacaa 420
agacttatac caaatccttt cagatcgcgt ccacgtttta catcccgaag gctacttaat 480
tacccctgca tggctgtggg aaaaatatgg attacgtccg gatcaatggg ccgattaccg 540
tgctttaacc ggtgatgaat cagataacct gccagatgtt aaagggattg gagaaaaaac 600
tgcctgtaaa ttgttagatg aatggggctc tttggaagca ctgttaaaaa accttgatcg 660
tctcaaacct gccatccgcg aaaaaatcct ggcccacatg gatgacttaa aactgagctg 720
ggatcccgct aaagttcgta ccgacttacc tcttgaagtt gattttgcaa aacgccgtga 780
acctgatcgt gaacgccttc gtgcatttct tgaacgtctg gaatttggct ccttgttaca 840
tgaatttggc ctcttagaat cacccaaggc cctggaagaa gcactgtggc ctccacctga 900
aggcgccttt gttggttttg ttttgtctcg taaagaacct atgtgggccg atttactggc 960
attagccgct gcacgtggtg gtcgtgtcca tcgcgcacca gaaccttata aagcactgcg 1020
tgatcttaaa gaagctcgtg gtctcctcgc caaagactta tccgtattag cactccgcga 1080
gggtttaggg ctgccacctg gtgatgatcc aatgttactt gcatatctcc tggatccctc 1140
taatacaacc ccggaaggcg tggctcgtcg ttatggtggt gaatggactg aagaagctgg 1200
tgaacgtgcg gctttgtctg aacgcttatt cgctgacctg tggggccgtc tggaaggaga 1260
ggaacgctta ctctggttat atcgtgaagt tgaacgccca ctgtcagcag tacttgcgcg 1320
catggaagct accggggtcc gcttagatgt tgcctatctc cgtgctctga gtcttgaagt 1380
agccgaagaa attgcgcgcc tggaagccga agtatttcgt ctggccggtc acccgtttaa 1440
ccttaattcc cgtgatcaac tggaacgcgt tttgtttgat gaacttggcc tgcccgcaat 1500
tggtaaaact gaaaaaactg gtaaacgttc gacctccgcc gcagtccttg aagccctgcg 1560
tgaagcccac ccaattgtcg aaaaaatcct gcagtaccgg gaactcacga aacttaaatc 1620
tacctatatt gacccgctgc cgcgtctggt gcacccgaaa accggacgtc ttcacacccg 1680
ttttaatcaa actgctaccg cgactggacg tttaagctca tccgatccca acttgcaaaa 1740
tattcctgtc cgtaccccac tagggcaacg tattcgtaag gcgtttattg cggaagaggg 1800
ccacctgctg gttgcgctgg actacagcca gatcgaactg cgtgttctgg cgcacctgag 1860
cggtgacgag aacctgatcc gtgttttcca ggaaggcaaa gatattcaca ccgagaccgc 1920
ggcgtggatg tttggtgtgc cgccggaagg tgttgatggt gcgatgcgtc gtgcggcgaa 1980
gaccgtgaac ttcggtgttc tgtatggcat gagcgcgcac cgtctgagcc aggaactgag 2040
catcccgtac gaagaggcgg cggcgtttat tgagcgttat ttccagagct ttccgcaagt 2100
gcgtgcgtgg atcgcgcaca ccctggaaga gggtcgtaag aaaggctacg tggagaccct 2160
gttcggtcgt cgtcgttacg ttccggacct gaacgcgcgt gtgaaaagcg ttcgtaaagc 2220
ggcggagcgt atggcgttca acatggcggt gcaaggtacc gcggcggacc tgatgaagct 2280
ggcgatggtg aagctgtttc cgcgtctgcc ggaagtgggt gcgcgtatgc tgttgcaggt 2340
gcacgatgaa ctgctgctgg aggcgccgaa agagcgtgcg gaagaggcgg cggcgctggc 2400
gaaggaagtg atggagggtg tttggccgct tgcggtgccg ctggaagtgg aagttggtat 2460
cggtgaagac tggctgagcg cgaagggcta atatctaact aa 2502
<210> 15
<211> 2490
<212> DNA
<213> 人工序列
<220>
<223> 人工序列说明:合成多核苷酸
<400> 15
atgctgccgc tgtttgagcc gaaaggtcgt gtgctgctgg ttgacggcca ccacctggcg 60
taccgtacct tctttgcgct gaaaggtctg accaccagcc gtggtgagcc ggtgcaaggt 120
gtttacggct tcgcgaaaag cctgctgaag gcgctgaaag aagacggcga ggtggcgatc 180
gtggttttcg atgcgaaagc gccgagcttt cgtcacgaag cgtacgaggc gtataaagcg 240
ggtcgtgcgc cgaccccgga agacttcccg cgtcaactgg cgctgattaa ggagctggtt 300
gatctgctgg gtctggtgcg tctggaagtg ccgggctttg aagcggatga tgttctggcg 360
gcgctggcga agaaagcgga acgtgagggt tacgaggttc gtatcctgag cgcggaccgt 420
gatctgtatc agctgctgag cgaccgtatt cacctactgc atcccgaagg ctacttaatt 480
acccctgcat ggctgtggga aaaatatgga ttacgtccgg atcaatgggc cgattaccgt 540
gctttaaccg gtgatgaatc agataacctg ccaggtgtta aagggattgg agaaaaaact 600
gcccgtaaat tgttagaaga atggggctct ttggaagcac tgttaaaaaa ccttgatcgt 660
ctcaaacctg ccatccgcga aaaaattctg gcccacatgg atgacttaaa actgagctgg 720
gatcccgcta aagttcgtac cgacttacct ctcgaagttg attttgcaaa acgccgtgaa 780
cctgatcgtg aacgccttcg tgcatttctt gaacgtctgg aatttggctc cttgttacac 840
gaatttggcc tcttagaatc acccaaggcc ctggaagaag caccgtggcc tccacctgaa 900
ggcgcctttg ttggttttgt tttgtctcgt aaagaaccta tgtgggccga tttactggcc 960
ttagccgctg cacgtggtgg tcgtgtccat cgcgcaccag aaccttataa agcactgcgt 1020
gatcttaaag aagctcgtgg tctcctcgcc aaagacttat ccgtattagc actccgcgag 1080
ggtttagggc tgccacctgg tgatgatcca atgttacttg catatctcct ggatccctct 1140
aatacaaccc cggaaggcgt ggctcgtcgt tatggtggtg aatggactga agaagctggt 1200
gaacgtgcgg ctttgtctga acgcttattc gctaacctgt ggggccgtct ggaaggagag 1260
gaacgcttac tctggttata tcgtgaagtt gaacgcccac tgtcagcagt acttgcgcac 1320
atggaagcta ccggggtccg cttagatgtt gcctatctcc gtgctctgag tcttgaagta 1380
gccgaagaaa ttgcgcgcct ggaagccgaa gtatttcgtc tggccggtca cccgttcaac 1440
cttaattccc gtgatcaact ggaacgcgtt ttgtttgatg aacttggcct gcccgcaatt 1500
ggtaaaactg aaaaaactgg taaacgttcg acctccgccg cagtccttga agccctgcgt 1560
gaagcccacc caattgtcga aaaaatcctg cagtaccgcg aactcactaa acttaaatct 1620
acctatattg acccgctgcc gcgtctggtg cacccgaaaa ccggacgtct tcacacccgt 1680
tttaatcaaa ctgctaccgc gactggacgt ttaagctcat ccgatcccaa cttgcaaaat 1740
attcctgtcc gtaccccact agggcaacgt attcgccgcg catttatcgc agaggaaggt 1800
tggttgctgg tggcattaga ttatagccaa attgaattac gtgttcttgc gcatttatcc 1860
ggtgacgaaa atctcattcg tgtttttcag gagggacgtg atattcacac agaaaccgct 1920
tcatggatgt ttggtgttcc gcgtgaagcc gtcgacccgt taatgcgtcg cgctgcaaaa 1980
accattaatt tcggtgttct gtatggtatg agtgcacatc ggttatcaca agaactcgct 2040
atcccgtacg aagaagctca agcatttatt gaacgttatt ttcagagttt tcctaaggtt 2100
cgtgcttgga ttgagcgtac cctggaagag ggtcgtcagc gtggctacgt ggaaaccctg 2160
tttggtcgtc gtcgttacgt tccggatctg aacgcgcgtg tgaaaagggt tcgtaaagcg 2220
gcggagcgta tggcgttcaa catgcaggtg caaggtaccg cggcggacct gatgaagctg 2280
gcgatggttc gtctgttccc gcgtctgccg gaagtgggtg cgcgtatgct gctgcaggtt 2340
cacgatgaac tgctgctgga ggcgccgaaa gagcgtgcgg aagaggcggc gcaactggcg 2400
aaggaaacca tggagggtgt ttggccgctg gcggtgccgc tggaagtcga agtgggcatc 2460
ggtgaagact ggctgtcggc aaaagaataa 2490
<210> 16
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 人工序列说明:合成6xHis标签
<400> 16
His His His His His His
1 5
<210> 17
<211> 19
<212> DNA
<213> 人工序列
<220>
<223> 人工序列说明:合成引物
<400> 17
gaaggtgaag gtcggagtc 19
<210> 18
<211> 20
<212> DNA
<213> 人工序列
<220>
<223> 人工序列说明:合成引物
<400> 18
gaagatggtg atgggatttc 20

Claims (18)

1.一种突变A型DNA聚合酶,包含:
对应于野生型水生栖热菌(Taq)DNA聚合酶的一个或多个氨基酸残基551、788和798的突变,
其中所述突变聚合酶比野生型DNA聚合酶对聚合活性抑制剂具有更高的抗性。
2.如权利要求1所述的突变A型DNA聚合酶,包含D551R、V788L和A798E处的突变。
3.如权利要求1所述的突变A型DNA聚合酶,在选自52、99、109、128、154、259、268和739的氨基酸残基处包含一个或多个其他突变。
4.如权利要求3所述的突变A型DNA聚合酶,在L52A,I99M,A109E,K128I,H154A,A259R,R268G和S739R处包含突变。
5.如权利要求1所述的突变A型DNA聚合酶,与选自SEQ ID NO:1、2、3、4、5、6和7的氨基酸序列具有至少85%相同性。
6.如权利要求1所述的突变A型DNA聚合酶,包含SEQ ID NO:1,SEQ ID NO:2,SEQ IDNO:3,SEQ ID NO:4,SEQ ID NO:5,SEQ ID NO:6或SEQ ID NO:7。
7.如权利要求1-6中任一项所述的突变A型DNA聚合酶,其中所述突变A型DNA聚合酶在98℃下热稳定至少15分钟。
8.一种组合物,包含(i)如权利要求1-7中任一项所述的突变A型DNA聚合酶,和(ii)一种或多种选自下组的试剂:水性缓冲剂、金属离子、核苷酸、引物、探针、去污剂、染料、检测剂、靶核酸、抗凝剂和细胞裂解剂。
9.一种对靶核酸进行扩增的方法,所述方法包括:
使疑似含有靶核酸的测试样品与如权利要求1-7中任一项所述的突变聚合酶、与靶核酸特异性结合的至少一种引物以及核苷酸接触以形成混合物;和
使用靶核酸的序列作为掺入核苷酸的模板,在允许至少一种引物通过聚合酶延伸的条件下孵育所述混合物。
10.如权利要求9所述的方法,其中所述方法是PCR。
11.如权利要求10所述的方法,其中所述方法是qPCR、RT-PCR或ddPCR。
12.如权利要求9或10所述的方法,其中所述条件包括存在对野生型DNA聚合酶抑制性的浓度的野生型DNA聚合酶的抑制剂。
13.如权利要求9-12中任一项所述的方法,其中所述测试样品是血液样品或血液组分。
14.一种包含核苷酸序列的核酸,所述核苷酸序列编码如权利要求1-7中任一项所述的突变热稳定A型DNA聚合酶。
15.一种载体,其包含如权利要求14所述的核酸。
16.一种宿主细胞,其包含如权利要求15所述的载体。
17.一种生产多肽的方法,所述方法包括:
在允许核酸编码的多肽表达的条件下在培养基中培养包含所述核酸的宿主细胞,所述核酸包含核苷酸序列,所述核苷酸序列编码如权利要求1-7中任一项所述的突变A型DNA聚合酶;和
从所述培养的细胞或培养基纯化所述多肽。
18.一种用于扩增靶核酸的试剂盒,所述试剂盒包含(i)如权利要求1-7中任一项所述的突变热稳定A型DNA聚合酶,和(ii)选自下组的一种或多种试剂:水性缓冲剂、金属离子、核苷酸、引物、探针、去污剂、检测剂、染料、抗凝剂和细胞裂解剂。
CN201980008824.4A 2018-01-19 2019-01-15 突变dna聚合酶 Pending CN111684064A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862619394P 2018-01-19 2018-01-19
US62/619,394 2018-01-19
PCT/US2019/013673 WO2019143622A1 (en) 2018-01-19 2019-01-15 Mutant dna polymerases

Publications (1)

Publication Number Publication Date
CN111684064A true CN111684064A (zh) 2020-09-18

Family

ID=67299788

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980008824.4A Pending CN111684064A (zh) 2018-01-19 2019-01-15 突变dna聚合酶

Country Status (4)

Country Link
US (1) US10961518B2 (zh)
EP (1) EP3740591A4 (zh)
CN (1) CN111684064A (zh)
WO (1) WO2019143622A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112921015A (zh) * 2021-03-25 2021-06-08 山东大学 高特异性Taq DNA聚合酶变体及其在基因组编辑和基因突变检测中的应用
CN113881650A (zh) * 2020-10-07 2022-01-04 武汉爱博泰克生物科技有限公司 用于探针法qPCR的Taq DNA聚合酶突变体

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3922718A4 (en) * 2020-04-30 2022-03-23 Daan Gene Co., Ltd. HEAT-RESISTANT DNA POLYMERASE MUTANT WITH HIGH AMPLIFICATION ACTIVITY

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038673A1 (ja) * 2004-10-06 2006-04-13 Universal Bio Research Co., Ltd. 熱安定性又は熱活性dnaポリメラーゼ及びそれをコードするdna
US20110027833A1 (en) * 2009-07-31 2011-02-03 Holly Hogrefe Thermostable type-a dna polymerase mutants with increased polymerization rate and resistance to inhibitors
US20130034879A1 (en) * 2011-08-03 2013-02-07 Fermentas Uab DNA Polymerases
US20140113299A1 (en) * 2012-10-16 2014-04-24 Dna Polymerase Technology, Inc. Inhibition-resistant polymerases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759226B1 (en) * 2000-05-24 2004-07-06 Third Wave Technologies, Inc. Enzymes for the detection of specific nucleic acid sequences
DE69838521T2 (de) 1997-07-07 2008-05-21 Medical Research Council Methode zur Erhöhung der Konzentration von Nucleinsäuremolekülen
US7049101B1 (en) 1997-08-06 2006-05-23 Diversa Corporation Enzymes having high temperature polymerase activity and methods of use thereof
DE19810879A1 (de) 1998-03-13 1999-09-16 Roche Diagnostics Gmbh Polymerasenchimären
GB9900298D0 (en) 1999-01-07 1999-02-24 Medical Res Council Optical sorting method
EP1294863B1 (en) * 2000-05-24 2009-07-08 Third Wave Technologies, Inc. Detection of rna
GB0022458D0 (en) 2000-09-13 2000-11-01 Medical Res Council Directed evolution method
GB0127564D0 (en) 2001-11-16 2002-01-09 Medical Res Council Emulsion compositions
US7560260B2 (en) 2002-07-25 2009-07-14 Bio-Rad Laboratories, Inc. Compositions with polymerase activity
ATE407202T1 (de) 2003-05-07 2008-09-15 Novozymes As Enzymvarianten von subtilisin (subtilasen)
NZ544952A (en) 2003-05-30 2009-12-24 Univ Illinois Gene expression profiles that identify genetically elite ungulate mammals
AU2004203649B2 (en) 2003-08-12 2006-01-12 F. Hoffmann-La Roche Ag Thermostable Taq polymerase fragment
WO2005045015A2 (en) 2003-11-03 2005-05-19 Medical Research Council Polymerase
US7462475B2 (en) 2004-05-20 2008-12-09 Dna Poleymerase Technology, Inc. Use of whole blood in PCR reactions
WO2005113760A2 (en) 2004-05-20 2005-12-01 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Thermostable y-family polymerases and chimeras
WO2008050104A1 (en) 2006-10-23 2008-05-02 Medical Research Council Polymerase
CN102257136A (zh) 2008-11-03 2011-11-23 卡帕生物*** 嵌合dna聚合酶
JP5809059B2 (ja) 2008-11-03 2015-11-10 カパ バイオシステムズ, インコーポレイテッド 改変a型dnaポリメラーゼ
WO2010062779A2 (en) 2008-11-03 2010-06-03 Kapabiosystems Modified dna polymerases
US20110014612A1 (en) 2009-03-27 2011-01-20 Life Technologies Corporation Polymerase compositions & methods
WO2012097318A2 (en) * 2011-01-14 2012-07-19 Kap Abiosystems Modified dna polymerases for improved amplification
CA2831180C (en) 2011-04-11 2017-02-14 Keith Bauer Dna polymerases with improved activity
US8470573B2 (en) 2011-06-21 2013-06-25 Bio-Rad Laboratories, Inc. Hybrid polymerases having the ability to produce long amplicons
EP3293274B1 (en) 2011-08-10 2020-04-01 Life Technologies Corporation Polymerase compositions
EP2986719B1 (en) 2013-12-06 2020-07-29 Bio-Rad Laboratories, Inc. Fusion polymerases
US9758773B2 (en) 2014-02-14 2017-09-12 Agilent Technologies, Inc. Thermostable type-A DNA polymerase mutant with increased resistance to inhibitors in blood
EP4141126A1 (en) 2015-10-01 2023-03-01 Life Technologies Corporation Polymerase compositions and kits, and methods of using and making the same
CN110382690B (zh) 2017-02-16 2024-05-24 生物辐射实验室股份有限公司 新型逆转录酶及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038673A1 (ja) * 2004-10-06 2006-04-13 Universal Bio Research Co., Ltd. 熱安定性又は熱活性dnaポリメラーゼ及びそれをコードするdna
US20110027833A1 (en) * 2009-07-31 2011-02-03 Holly Hogrefe Thermostable type-a dna polymerase mutants with increased polymerization rate and resistance to inhibitors
US20130034879A1 (en) * 2011-08-03 2013-02-07 Fermentas Uab DNA Polymerases
US20140113299A1 (en) * 2012-10-16 2014-04-24 Dna Polymerase Technology, Inc. Inhibition-resistant polymerases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GENBANK DATABASE: "Genbank:WP_027881614.1,DNA polymerase I [Meiothermus rufus]", GENBANK DATABASE *
GENBANK DATABASE: "Genbank:WP_071676319.1,DNA polymerase I [Thermus brockianus]", GENBANK DATABASE *
GENBANK DATABASE: "Genbank:WP_081641628.1,DNA polymerase I [Thermus thermophilus]", GENBANK DATABASE *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113881650A (zh) * 2020-10-07 2022-01-04 武汉爱博泰克生物科技有限公司 用于探针法qPCR的Taq DNA聚合酶突变体
CN112921015A (zh) * 2021-03-25 2021-06-08 山东大学 高特异性Taq DNA聚合酶变体及其在基因组编辑和基因突变检测中的应用
WO2022198849A1 (zh) * 2021-03-25 2022-09-29 山东大学 高特异性Taq DNA聚合酶变体及其在基因组编辑和基因突变检测中的应用

Also Published As

Publication number Publication date
US20190225951A1 (en) 2019-07-25
EP3740591A4 (en) 2022-02-23
US10961518B2 (en) 2021-03-30
WO2019143622A1 (en) 2019-07-25
EP3740591A1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
DK2971080T3 (en) METHODS FOR AMPLIFICATION AND SEQUENCE USING THERMOSTABLE TTHPRIMPOL
EP1152062B1 (en) High temperature reverse transcription using mutant DNA polymerases
EP2539472A2 (en) Fast pcr for str genotyping
CN111684064A (zh) 突变dna聚合酶
KR101622442B1 (ko) 3’―미스매치 구별이 증가된 dna 중합효소
US10590400B2 (en) DNA polymerases with increased 3′-mismatch discrimination
US10544404B2 (en) DNA polymerases with increased 3′-mismatch discrimination
JP7014256B2 (ja) 核酸増幅試薬
CN112703248A (zh) 具有改良链置换能力的突变型dna聚合酶
EP3768832B1 (en) Dna polymerases for efficient and effective incorporation of methylated-dntps
US12043851B2 (en) DNA polymerases for efficient and effective incorporation of methylated-dNTPS
JP6638399B2 (ja) 核酸増幅の正確性を向上させる方法
KR20200123458A (ko) 돌연변이를 도입하는 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination